like boost higher rx volum
like face largest hit volum lower
rate commerci insur patient amount
destock occur late biggest swing
factor estim
potenti impact key mileston across coverag expect
slight rx tailwind patient stockpil medicin estim
rx broadli across differ channel march outsid
impact would also expect distributor potenti consid destock
ahead declin demand howev given higher demand
continu end march clear us destock
occur compani preemptiv lower
volum given expect lower rate new diagnos
therefor new patient start broadli announc
mani compani clinic trial paus slow delay pleas see
insid complet list compani comment relat impact
timelin key mileston
ow pt ep mse total
revenu vs con driven enbrel prolia taken
conserv approach given concern around covid destock focu
area includ updat guidanc relat covid especi
impact prolia timelin relat key mileston
otezla tezepelumab
uw pt ep mse in-lin total
revenu slightli higher ep due typic season low
spend focu area includ time updat relat
aducanumab file covid impact key mileston studi readout
specif impact covid spinraza significantli lower
spinraza estim especi outsid us assum new
case growth limit adult
ew pt ep mse slightli
total revenu vs con like due differ
destock forecast would also note mani hiv product especi
biktarvi appear help covid-rel buy would expect
revers focu area includ management plan
evalu car-t busi rel recent bristol verdict see
management next step nash expect focu patient look
forward data easl covid relat impact busi coupl
plan remdesivir
ow pt ep mse slightli
pleas see price target chang exhibit
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
total revenu vs con driven typic season
conserv view switch due covid overal management alreadi
guid potenti impact busi expect
much new inform call
ew pt updat model new account
structur management outlin recent thu model directli
compar current consensu broadli expect in-line quarter though
may messi given account transit overal remain focus
impact eylea delay offic visit due covid lower
anti-vegf market growth rate flat global versu prior high-
singl digit growth management progress covid pipelin especi
antibodi therapi impact management clinic trial timelin especi
ew pt ep line total revenu
assum slow new patient due covid look
management guidanc around full impact overal expect rare diseas
busi rel resili pipelin remain focus
potenti biosimilar competit management abil execut light covid
suggest epidiolex sale would like line
current project quarter investor hope
continu growth label indic plu ad label use provid
upsid also seek understand potenti impact
go forward investor like continu focu
perform onpattro compani report project
sale quarter investor also pay attent givlaari
first full quarter market project sale overal expect
perform onpattro givlaari overli impact
pandem compani suffici inventori drug
raw materi meet project demand plu appropri safeti stock
investor listen management commentari regard potenti impact
onpattro sale go forward well on-going launch givlaari
investor interest hear present data phiii
voyag trial fda support nda avapritinib gist
investor curiou know alreadi happen insight
may gain point pdufa date nda may
ow pt ow pt ew pt
management recent note earli april limit commerci impact
observ jakafi date expect investor focu heavili
potenti impact long-stand social distanc measur
throughout may sale result impact
jakafi sale guidanc also expect investor focu
impact may multipl regulatori data-rel catalyst
anticip throughout year includ tafasitamab pdufa date
august phiii data jakafi chronic gvhd initi
bioequival data qd ruxolitinib among other expect
investor focu impact new patient start
tymlo enrol phiii wearabl studi abaloparatid patch
believ key area focu impact virtual field
forc andexxa uptak continu observ regard dur
andexxa impact eu uptak reimburs procedur uk
germani due relat disrupt
go absolut basi forward price-to-earnings ev/ebitda multipl
lowest rang histori averag forward price-to-earnings almost half
broader market trend revers recent month driven
rel consist valuat across biotech broadli compar
healthcar pharmaceut full data emphasi present
exhibit
recent month biotech ev ebitda metric increas roughli
consist healthcar industri sector broadli
exhibit rel price forward earn rel
exhibit rel ev ebitda rel
importantli amid broader market sell-off healthcar sector gain
percent market cap
exhibit percent market cap
exhibit percent market cap
impact larg cap valuat recessionari histori
though larg cap biotech often seen defens play mani larg cap name
seen pressur result broader market condit despit trail pe
multipl remain rel constant albeit declin slightli earli
februari late march
exhibit impact larg cap biotech ratio
offer comparison indic versu
recessionari period respect defin nation
bureau econom research nber crisi
demonstr rel insul versu appear
trade line broader market though note sector whole
morgan stanley research bloomberg nation bureau econom research
morgan stanley research bloomberg nation bureau econom research
posit runway estim
compani subject substanti fund risk estim
base proxi current cash burn smid-cap coverag averag
quarter liquid cash runway addit fund requir
methodolog estim cash burn runway follow sum
total liquid asset ce short term invest smid biotech
coverag divid figur oper neg proxi
cash burn determin number years/period compani could
sustain current rate account discrep year-end file
recent fund chang gather equiti rais sourc liquid
date publish includ valu estim
liquid asset
exhibit februari present smid cap biotech perform vs market cap
exhibit februari present smid cap biotech perform vs market
exhibit februari present smid cap biotech perform vs market cap
summar compani commentari impact busi result covid-
management releas statement regard impact found management maintain
time releas phiii vadadustat trial begin
compani cash available-for-sal secur total
last well compani intent tap at-the-
market atm program trial report earliest
management cite expect delay on-going trial updat page
may found
alnylam expand collabor util sirna target
coronavirus partnership split collabor focus three host
factor inbclud compani work gener
data enabl clinic trial alnylam suffici inventori drug raw
materi meet project demand compani also appropri safeti stock
current anticip signific impact manufactur
commerci product product candid clinic trial
initi collabor cover
identifi potenti virus-neutr human antibodi treat patient covid-
collabor leverag immunology/antibodi platform
adapt high throughput screen platform also util insight
subsidiari decod genet analyz patient previous infect
viru see approach fundament similar regeneron full press
releas found management indic impact
time on-going clinic trial result
top-line result eprenetapopt phase md expect by-
year end due slower enrol result management remain confid
abil report data year-end target patient enrol
activ enrol site remain potenti impact earlier
phiii adapt studi efgartigimod mg remain track
disrupt management highlight primari endpoint data
collect major patient move onto open-label extens
studi management explor remot safeti monitor patient potenti at-
home dose fcrn trial management note global itp/cidp trial enrol
could interrupt due patient inabl travel test site though detail
reveal potenti impact becom clear cusatuzumab
aml management note oncolog still remain prioriti treatment
hospit posit trial interrupt may occur nonetheless
thu far delay interact regul full eu bu
takeaway note found
minim impact near- long-term mileston
management indic on-going data updat phi fact phii fabri diseas
like though time firm continu enrol resum
hospit allow on-going data collect phi/ii cystinosi patient occur
time firm second patient set dose clinic
site allow first patient phi/ii gaucher diseas trial set dose
may though time could delay ultim time dose
clinic site allow management commentari impact may found
management expect neg impact broad busi oper
china includ commerci sale regulatori interactions/inspect clinic
trial recruitment/particip least possibl longer tislelizumab
launch track well approv zanubrutinib china
treatment patient r/r mcl r/r cll/sll routin busi
 activ less impact full note
management cite expect impact on-going clinic trial result
management announc fda author compani initi
phii studi vazegep treatment infect associ
pulmonari complic full press releas found
management announc program impact collect
management expect least delay on-going clinic studi due
management clarifi data releas plan remain track multipl
myeloma management expect on-going trial karmma-
earli line mm patient impact given delay recruit importantli
management clarifi bla submiss remain track scd management
remain track provid regulatori updat potenti acceler approv
pathway b-thalasemmia zynteglo us file management state
discuss fda regard modif releas assay on-going
expect roll bla submiss timelin shift
ex-u management believ pandem impact
time zynteglo market access reimburs eu govern
focu pandem respons full detail impact see full note
management highlight abil maintain time two recent data updat
re-affirmed time upcom near-term mileston management commentari
impact may found recent releas
management anticip delay report acut safeti data first cohort
descaart trial due pandem full press releas
data phase galactic-hf still expect management still believ
complet enrol meteor achiev despit paus
enrol initi data redwood-hcm still expect management see
impact reldesemtiv expect provid updat discuss
regul call remain posit begin phase
enrol phase trial redwood-hcm trial suspend
management announc paus sever clinic trial management highlight
uncertainti around relev impact clinic trial busi
oper management announc follow updat on-going clinic trial
phi/ib trial paus management track select either
recruit addit patient etv id observ
biomark studi paus phi/ii trial track start
phib trial complet dose primari analysi management reiter
expect make final decis path forward
phi trial hv complet dose enrol addit subject
paus management note expect clinic delay due
manufacturing/supply-chain problem highlight expect current
cash posit fund busi origin note
recent put note highlight well posit respect
note tazverik fl like approv mutant
wild type follicular lymphoma fl patient epithelioid sarcoma es
get med despit pandem market effort fl
disrupt saleforc alreadi place team alreadi plan emphas
non-person market edetail effort part launch
management current evalu treatment diseas caus viral
infect
forti seven delay initi phi trial healthi volunt
note acquisit complet
phiib trial losmapimod fshd fulli enrol result
studi origin expect management announc despit enrol
complet suspens clinic trial throughout countri due
may impact readout timelin note primari endpoint phiib studi
activ muscl key endpoint muscl fat
fraction requir use mri result virtual evalu key endpoint
imposs would expect delay case particip
physic visit trial site statist power may also impact mani
patient data miss origin note
management current see impact file timelin filgotinib ra
gilead management decid halt recruit filgotinib trial though note phiii uc
recruit complet data still expect toledo management still
decid whether start first toledo studi preliminari step still
taken advanc toledo trial origin plan start
management discuss site recruit on-going ipf
isabela though slow recruit begun pick back east
follow presum peak case conting plan develop
emphasi home-test ipf patient oa roccella management
note final patient one visit left though especi import
patient receiv mri on-site novesa ssc pinta
ipf trial remain track fulli recruit readout expect
full eu bu takeaway note found galapago webpag
found
commerci side darzalex sale yet impact though
increas hospit bed occup could imped patient access drug therebi
impact revenu management note subq darzalex label expans still track
fda respons launch tepezza teprotumumab could
impact due reduc physician patient access recently-hir salesforc
management look toward like launch ofatumumab note june pdufa could
delay management note present data expect humax-axl-adc
timelin may impact full eu
bu takeaway note found
management provid sever recent updat remdesivir accompani ceo daniel
oday open letter management present follow time tabl preliminari
data remdesivir late april gilead open-label trial patient sever
 late may open-label trial patient moder
 late may niaid double-blind placebo-control trial patient
june inserm trial patient expect first
data read-out gilead trial sever case made avail mid-
may management also note trial china patient sever
discontinu due low enrol nejm articl gilead author
present remdesivir data patient treat compassionate-us
protocol patient ventil get ecmo treatment
time manuscript public patient discharg
hospit die ventil clinic improv
seen patient half patient
receiv invas ventil extub new safeti signal observ
import caveat first random control arm studi second
sampl size small compassionate-us patient third
program collect viral load data confirm antivir effect remdesivir
associ baselin viral load viral suppress clinic
respons management state continu ramp suppli remdesivir
materi patient addit octob
addit management initi uk two phiii random studi
evalu safeti efficaci remdesivir patient moder sever
management note ema provid recommend use
remdesivir compassion use eu
suspend in-person interact salespeopl scale-up digit
outreach healthcar profession payer management provid addit updat
invest commun need origin press releas
management observ commerci impact date jakafi management note
suppli chain issu date current impact observ fda timelin
pemigatinib tafasitamab capmatinib nda submiss rux cream
ad continu anticip management commentari provid recent
corpor present avail
management suspend revenu guidanc arikayc result on-going
uncertainti management note trend patient metric impact
dramat importantli management see spread point-in-tim
disrupt uptak arikayc management current earli stage evalu
anim model treatment acut respiratori distress syndrom
ard known sequela patient recov spread
yet impact suppli chain mid-march
month finish arikayc product hand product continu
suffici api facilit product end withdrawn in-
person sale arikayc mitig effect decis management note full
extent digit market capabl current deploy full note
ioni remain well fund cash compani
point seen signific impact commerci product drug manufactur suppli
chain signific delay regulatori meet
conduct virtual task forc instal continu evalu
clinic trial on-going basi minim delay point specif delay
highlight compani indic trial differ could
differ impact method handl current environ link
ioni full commentari impact may found
recent note highlight impact found materi impact
suppli linzess meet commerci demand time phii data
pain ibs-d remain target data phiii trial
refractori gerd delay beyond compani cash
book restructur debt august cash interest
payment reduc earliest debt matur recent updat
ironwood impact may found
annual file management note kodiak intend submit one ind
china management note intent may impact
spread clear alter plan disclos yet
management highlight impact point press releas
margetuximab bla breast cancer remain track like
fda decis also expect phiii mahogani data remain track
patient enrol oncolog trial continu treat enrol
expect slow phii cmv phi zika trial fulli enrol management expect
delay interrupt patient receiv second vaccin management believ
enough inform relat phii cmv trial defin immunogen
look extend potenti vaccin window accommod
impact management paus on-go rare diseas trial
work site personnel determin begin re-enrol
vaccin management announc enrol go
well expect initi data late spring summer pre-clin challeng studi
on-going parallel phi trial initi data expect come
month management expect run phiia trial ensur safeti toler
vaccin move pivot studi addit efficaci need
establish naiv patient ensur benefici prevent diseas management
highlight cash cash equival anticip lower
spend given evolv outbreak management plan provid updat
financi guidanc earn management highlight secur raw
materi month come believ management take necessari
precaut insur integr trial maintain remain
focus initi clinic pre-clin data associ
treatment full note
explor data remain track mse may/jun patient visit
occur treatment period phase data still expect
like esc heart failur may enrol dose complet
compani delay begin new studi phase valor-hcm phase
hfpef danicamtiv phase dcm compani suspend rollov
patient explor mava-lt delay enrol healthi volunt
phase
compani recent issu elabor sale forc restructur
conjunct impact link found correspond note
compani elimin hospital-bas sale forc begin
build commun base forc stay-at-hom mandat relax
downsiz save cash per quarter meaning consid cash
rais like need nbrv current book
data four cohort crinecerfont phase studi adult congenit
adren hyperplasia patient present endo on-line meet
june data first three cohort includ abstract
potenti approv opicapon parkinson still track april pdufa
date neurocrin delay potenti launch later year better clariti
adequ commerci suppli partner bial stabl market environ
better continu care compani temporarili paus enrol
valbenazin phase chorea huntington diseas crinecerfont phase
studi pediatr patient neurocrin expect disrupt
abil suppli ingrezza neurocrin partner voyag announc
temporarili paus screen new patient trial parkinson
diseas due pandem studi remain track
begin
delay initi chemotherapi combin
trial phase phase biomark data still expect
mid-year phase data expect delay vs
management issu releas avail note andexxa field forc current
virtual andexxa suppli chain distribut structur current
result site paus enrol screen phase
propel studi parkinson prevail still expect report interim data
subset patient compani reiter timelin trial initi subject
delay provid phase type gaucher diseas
progress phase type gaucher diseas proclaim phase
frontotempor dementia
management yet outlin specif area impact
compani issu releas see note broadli indic
tymlo sale forc current virtual tymlo sale manufactur could
neg impact enrol phiii studi underway could
management cite explicit impact timelin though regeneron prepar
start large-scal manufactur two antibodi cocktail mid-april expect
initi first clinic trial earli summer full therapeut note
management recent comment impact press releas
prior ceo step expect recent roll nda complet board
search continu perman replac program trial continu
follow announc restructur larg unrel management
note zulresso revenu may impact spread viru management
announc plan provid revenu guidanc expect lower
oper expens full note restructur
recent wrote note well posit weather storm
respect management recent indic softwar busi
continu perform could neg impact softwar revenu
relat disrupt seem disrupt wi like modest
long haul management expect episod benefit busi
pharma/biotech embrac cost effici approach
management emphas anticip impact fda review
tucatinib nda pdufa date management expect expect impact on-going
clinic trial specifi like affect impact
adcetri padcev suppli expect management halt in-person sale pursu
digit market approach possibl full detail
expect impact drug suppli enrol on-going clinic trial
data phiii trial still expect trial
physician gener abl continu follow patient collect
data safeti efficaci endpoint compromis ompani
recent complet financ current cash last
management note outlook busi remain unchang suppli
chain unaffect despit pressur management made proactiv
chang on-going plan clinic trial detail yet
provid read origin press releas
compani receiv inform fda potenti delay
review inebilizumab nmosd pdufa june proceed
assumpt time remain track interim readout year
cutan lupu erythematosu cle remain track patient
cohort alreadi enrol viela decid paus enrol
phase sjogren syndrom phase midora studi
rheumatoid arthriti ra week time start inebilizumab phase
myasthenia gravi mg phase diseas remain track
mid-year management indic suffici drug suppli potenti launch
implement mitig plan prevent delay suppli chain
voyag temporarili paus screen new patient trial
parkinson diseas due pandem studi remain
track begin
compani recent submit nda dasiglucagon interrupt laboratori
base effort point minor earli pipelin suffici maintain
clinic trial initi prior pandem appear continu
littl impact work minim patient visit respect
patient screen new patient screen minim impact chi
trial sb studi
nc chang price
vadadustat drive akebia share
pt deriv dcf use discount rate termin growth rate
beyond valu akebia nephrolog program
equal-weight ahead phiii
equal-weight ahead phiii
major cardiac event mace data
major cardiac event mace data
see vadadustat therapi
benet might necessari success
vadadustat exce expect allow
therapi take addit share epo
vadadustat launch
vadadustat launch drug prole
allow success howev ampl
risk remain program lead risk
vadadustat fail compani valu cash
top-line phiii data trial vadadustat
top-line phiii data trial vadadustat
non-dialysi patient anemia ckd
main valuat driver perceiv
clinic regulatori risk vadadustat
ckd dialysi set
anoth key driver perform
view explan region hierarchi
vadadusat data show therapi
substanti safer esa lead
remov black box label
mace data unabl show vadadustat
safer esa
auryxia continu under-perform
akebia might need rais addit fund
issu equiti
note suffici broker suppli
consensu data metric
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
cost expens
product revenues/royalti
cash equival
avail sale secur
prepaid expens current asset
properti equip net
defer revenu net current portion
accumul comprehens incom loss
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
prepaid expens asset
accru expens liabil
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas market secur
sale matur market secur
net use invest activ
flow financ activ
proce exercis stock option equiti
proce issuanc common stock
chang equival
equival begin year
chang due restat
equival end year ex restrict cash
market secur restrict end year
recent approv drug advanc pipelin drive valu
pt deriv dcf use discount rate termin growth rate
beyond valu alnylam advanc proprietari rnai program
overweight alnylam
overweight alnylam investor
continu focu onpattro well
recent launch givlaaria move
increasingli also expect
investor emphas pipelin candid
lumasiran inclisiran tusiran
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
attr platform highli success givlaari
attr platform highli success givlaari
assum onpattro follow-on aln-
highli success form
attr givlaari lumasiran
launch sell well fitusiran
inclisiran abl success gain
approv appli modest pipelin
valu drug includ cemdisiran
launch lumasiran launch
launch lumasiran launch
onpattro strong launch attr
launch
drive sale model aip
revenu givlaari begin
lumasiran launch risk
adjust incorpor royalti
inclisiran appli modest pipelin valu
drug includ fitusiran
launch
launch
ling inclisiran hypercholesterolemia
report top line data phiii lumasiran illuminate-b trial
present complet illuminate-a result lumasiran
oxaleurop intern congress
fda approv inclisiran
fda/ema approv lumasiran
continu ramp onpattro initi
ramp givlaari well clinical/regulatori
updat lumasiran inclisiran
fitusiran drive share
view explan region hierarchi
research highest favor quintil
drug achiev higher expect sale
clinic data pipelin program exceed
pipelin failur proprietari
rnai therapi could lead substanti
chang share valu
neg safeti and/or efcaci data
therapeut program
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
million per share basi indic
net revenu collabor
cost expens
product revenu royalti
million per share basi indic
equival
prepaid expens current asset
properti equip net
defer revenu net current portion
total liabil sharehold equiti
million per share basi indic
adjust reconcil net loss net cash use oper activ
depreci amort
chang oper asset liabil
pre-paid expens asset
accru expens
purchas properti plant equip
purchas market secur
sale matur market secur
increas reduct restrict
net use invest activ
proce exercis stock option equiti
proce issuanc common stock
proce issuanc debt
net provid financ activ
chang equival
equival begin year
equival end year
market secur end year
car-t bcma scd beta-thalassemia gene therapi drive risk/reward
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
high share relaps set
assum larg portion elig scd
patient receiv gene therapi
signic portion new incid
thalassemia assum row penetr
assum strong launch
penetr front line patient
uptak beta-thalassemia us/eu
strong bcma car-t uptak line
moder sickl cell penetr
scd project peak ww sale
assum oral competit baselin
limit uptak gene therapi beta-
thalassemia assum penetr
develop market scd price
believ car-t bcma
achiev penetr late line therapi
driven peak sale believ
durat sale may modest due
competit bcma car-t
well bispec antibodi
valu lentiglobin penetr
sickl cell market beta-
thalassemia market believ pre-
condit limit uptak sickl cell
near-term launch off-set
signic need dilut fund
advanc commerci platform
lentiglobin fail
lentiglobin fail make us
market assum scd beta
thal make market model
cash-bas valu assum
launch
lentiglobin scd initi phiii studi
 multipl myeloma submiss karmma
data present
lentiglobin scd initi phiii studi
data updat
addit car-t data durabl data
earlier line therapi becom
addit data follow-up
lentiglobin beta-th scd studi underway
new clinic program either gene
therapy/edit car-t
view explan region hierarchi
research highest favor quintil
pipelin drug
regulatory/commerci headwind regard
approval/penetr us
market line therapi well earlier
eu regulatory/commerci headwind
us
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
base busi brineura vosoritid valrox drive valu
naglazym kuvan aldurazym pipelin vosoritid valrox greatest
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
leader orphan opportun
leader orphan opportun biomarin
uniqu player core
compet orphan drug set
apart larg cap target
market larger popul
strength base busi establish
strength base busi establish
valu commerci product expect
reach revenu given natur
market outsid kuvan generic/biosimilar
competit unlik allow base
busi creat valuat backstop
deep pipelin offer plenti
deep pipelin offer plenti
opportun upsid
opportun upsid biomarin
deep wide product pipelin two
drug expect launch
vosoritid valrox possibl
blockbust contribut upsid
extra strength pipelin
assum expect growth
base busi drug pipelin
vosoritid valrox becom even larger
driver valu
assum base busi perform well
come year also trifecta
vosoritid valrox bmn launch
model impli po
pipelin current approv drug
assum drug pipelin
unabl gener satisfactori result
addit risk bear scenario
vosoritid achondroplasia pre-submiss meet
author discuss market applic
valrox hemophilia updat vg/kg dose
updat vg/kg dose phii studi
valrox hemophilia potenti approv eu review
start jan last day
valrox hemophilia data phiii studi
pipelin opportun near-term focu
pipelin opportun near-term focu
investor focu pegvalias launch
vosoritide/valrox potenti blockbust
find patient drive sale base
find patient drive sale base
busi key base busi drug still
view explan region hierarchi
research highest favor quintil
neg updat valrox
focu orphan asset price could impact
investor view base business/pipelin
upsid particularli impact termin
valu busi
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
demonstr safeti human ip resolut success drive r/r
pt deriv dcf use discount rate termin growth rate
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
therapi launch us
eu treat cure
address popul
command premium price gener
peak ww sale edita
also abl realiz sale
addit therapi car-t
dmd cf
therapi launch
us eu treat cure
address popul
gener peak ww sale
edita abl develop success
therapi car-t hematolog dmd
cf achiev sale
ew edita crispr gene
edit platform derisk
oper standpoint gear
deliveri long-term safeti
clinic relev dose human need
proven
edita system modular approach
may allow differenti
initi risk prove gene edit
work human eye immun
privileg provid small contain
area sufcient quantiti vector
deliv safe
see signic long-term potenti
remain ew initi therapi
derisk clinic
edita abl commerci
therapi result valuat cash
program select candid compound
nk-cell program present vivo preclin proof-of-
concept data engin ipsc-deriv nk cell
neurolog indic program establish vivo
preclin proof-of-concept collabor askbio
conduct rst clinic trial
clinic hematolog diseas
genet diseas lung liver
pipelin program succeed develop
competitor drug achiev
ip outcom limit edita freedom
develop risk associ earli natur
pipelin timelin long initi
competitor could inuenc investor
percept stock
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
losmapimod efcaci phase ii studi drive risk/reward
pt deriv discount cash ow analysi assum discount rate
termin growth valu assum peak impli us market share fshd
adjust use probabl success po
believ fulcrum proprietari
target discoveri platform yield
import small molecul target genet
believ losmapimod promis
compound demonstr target
engag fshd higher
typic phiib probabl success clinic
studi see upsid potenti
acceler approv data
believ manag continu
nd genet target exploit
small molecul see potenti
phiib data biomark
earli clinic data sufcient
acceler approv losmapimod
preclin program advanc earli
clinic studi
losmapimod approv full phiii
losmapimod approv
losmapimod meet primari endpoint
phase ii thu demonstr potenti
treat fshd fda requir full
clinic program long-term follow-up
fshd patient scenario fulcrum
requir conduct phase studi
losmapimod fail receiv regulatori
approv trade cash value-per-share
losmapimod fshd type-c meet fda discuss
whether biomark use surrog endpoint
el-pfdd meet fda
losmapimod fshd data present american
academi neurolog
losmapimod fshd readout proof concept phiib
studi fshd patient may delay due
data demonstr efcaci fshd patient
expect
demonstr efcaci fshd patient expect
losmapimod succe clinic develop
poor efcaci would like caus investor
question valu fulcrum drug discoveri
investors/regul disregard avail
safeti data gsk prolong timelin
delay timelin posit data
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
market penetr voxelotor drive risk/reward
signic unmet medic need
signic unmet medic need
voxelotor oral dose potenti
diseas modifi therapi posit well
compet market new
therapi decad market
share suggest us peak sale
market assumpt leav room
market assumpt leav room
competit current model
peak penetr hbss leav room
gene therapi believ oral dose
could prefer gene therapi could offer
cur therapi could
prefer patient
despit posit aspect believ
current valuat reect peak sale
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
peak voxelotor penetr hbss
peak voxelotor penetr hbss
demonstr abil modifi lt
marker scd pain sickl crise
thrombot event new standard
care assum limit competit
gene therapi
peak voxelotor penetr hbss
peak voxelotor penetr hbss
patient assum clinic success
voxelotor compar success gene
therapi voxelotor gene therapi split
patient popul
voxelotor fail case assum
residu cash valu
oxbryta scd follow-up data phiii studi
commerci launch voxelotor
view explan region hierarchi
research highest favor quintil
voxelotor fall short penetr
greater success competitor therapi
gene therapi
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
durat hcv sale hiv patent expiri cart/pipelin drive risk-reward
equal-weight believ
offer signic downsid
protect management engag organ
rebuild compani return
sustain top-lin growth take time
signic return capit share
repurchas low forward price-to-earnings offer
core hiv franchis protect
tail durat remain
key investor debat greater
pipelin clariti expect
termin multipl inect posit
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
less rapid eros hcv franchis
less rapid eros hcv franchis
hiv product revenu reach
hcv busi gener sale
sale yescarta
lgotinib gilead
rapid hcv eros lower pipelin
rapid hcv eros lower pipelin
success bull case
success bull case hiv product
revenu reach hcv
busi gener sale
sale yescarta lgotinib
gilead
view descript risk reward theme
stabl hiv revenu quick hcv
stabl hiv revenu quick hcv
busi eros minim pipelin
busi eros minim pipelin
success hiv product revenu
hcv busi gener
sale littl pipelin valu
close acquisit gilead
initi phiii enhanc magrolimab azacitidin vs
azacitidin higher risk md
data phiii studi lgotinib ulcer coliti
remdesivir preliminari data sever
remdesivir preliminari data adapt random
main driver hiv hcv car-t
franchis pipelin capit deploy
repres driver
potenti pipelin upsid associ
china india
view explan region hierarchi
research highest favor quintil
better expect pipelin success key
unexpect competit hiv
rapid hcv eros appreci
failur car-t achiev signic market
penetr failur meaning expand
signic delay regulatori progress
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
success use partner proprietari program drive r/r
pt deriv dcf use discount rate termin growth rate
beyond valu proprietari partner gene therapi program
strong uptak indic
commerci proprietari
partner program model strong
uptak indic proprietari
program
hofh mp wet respect
gener peak sale
partner program mp iiia sma
partnership ultragenyx dimens
dmd gene therapi sale gener
peak royalti revenu
modest uptak indic
commerci proprietari
partner program model modest
uptak indic proprietari
program
hofh mp wet respect
gener peak sale
partner program mp iiia sma
partnership ultragenyx dimens
dmd gene therapi revenu gener
peak royalti revenu
believ compani
technolog alreadi broadli
transform method safely/effect
target clear endpoint
reduct hofh gag reduct
mpsi mpsii
arrang de-risk platform help
reduc binari risk face tradit
success licens program use
vector/deliveri regenxbio
program would reduc technic risk
face proprietari program
recent posit gene therapi data
help de-risk broader gene therapi
failur commerci proprietari
partner program receiv
royalti novarti
gener product relat revenu
bear case consist cash value-per-share
well valu royalti novarti
sma program eu
 wamd initi phii trial use suprachoroid
 hofh interim data updat phi/ii trial
 updat program
 wamd one-year data cohort
data/upd wet
advanc
program mp mp ii respect
updat zolgensma sale
research highest favor quintil
pipelin program succeed develop
competitor drug achiev
pipelin failur partner proprietari
neg safeti efcaci data gene
therapi program develop
either technolog license gene
therapi compani use vector outsid
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
note suffici broker suppli
consensu data metric
trikafta uptak life-cycl manag oper margin drive risk-reward
ow vertex see vertex
clear leader cf therapi believ
manag potenti deliv
ep overtim
efcaci data aatd mice model
suggest efcaci corrector
human therefor model includ
risk-adjust revenu corrector
believ potenti
competit cf believ vertex
signic advantag posit
on-market drug treat cf
popul model share
competitor long-term
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
trikafta penetr us
assum life-cycl extens extend
franchis also assum
penetr tripl therapi us
eu het/min
homozygot patient ww sale
cf aatd us eu
commerci success key
trikafta penetr us
assum mainten key cf franchis
life-cycl extens also assum
penetr tripl combin
homozygot heterozygot us
eu risk-adjust peak ww sale
cf aatd
view descript risk reward theme
trikafta penetr us
penetr us eu total
peak ww sale cf aatd
therapi peak
preclin compound advanc two new compound
trikafta cf ema approv eu
 aatd data updat phii studi patient
 fsg initi poc phii studi focal
 hemoglobinopathi data updat phi/ii
main driver vertex uptak
current therapi orkambi/kalydeco/trikafta
development/uptak corrector
china india
view explan region hierarchi
research highest favor quintil
competitor drug fail clinic fail achiev
trikafta penetr fall short expect
kalydeco sale fail meet expect
data clinic candid
data competit exce
clinic trial nda ling
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
po anti-ag market well oa knee drive risk/reward
deriv pt discount cash ow analysi assum wacc
termin growth rate revenu driver model osteoarthr
oa addit program contribut
manag pioneer novel
biolog senesc cell
opportun deliv step-funct chang
treatment chronic diseas
preclin model support
impact sasp factor senesc
suggest benet
remov senesc cell
oa offer proof-of-concept model
clear biomark clinic endpoint
po oa
po oa drive peak ww sale
coupl probabl
success penetr anti-ag market
broadli
po oa
po oa drive peak
ww sale coupl probabl
success penetr anti-ag market
broadli
program fail valu compani
cash
 ophthalmolog initi fih studi
follow-up long-term chronic data oa
addit ind ling follow-up product
ophthalmolog treatment
 oa top-line data phii trial
oa knee
 oa data phib trial oa
pipelin drug succeed develop
competitor drug fail achiev expect
initi program fail investor like
discount platform
competit calico/restorbio
oa program may right target test
follow-up dose period may
long enough kinet remov snc
see respons unknown
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
note suffici broker suppli
consensu data metric
note suffici broker suppli
consensu data metric
efcacy/safeti phase iib drive risk/reward
pt deriv discount cash ow analysi assum discount rate
termin growth valu assum peak impli us market share scd
adjust use probabl success po
believ imara promis drug
of-concept pharmacolog safeti
derisk phi/phiia studi
think phiib achiev
hbf rise threshold would
like requir registr given
alreadi achiev mean
hbf rise phiia drug exposur
phiib studi expect higher
phiia assign po
catalyst help us reassess
efcacy/safeti includ phiia
data scd interim
phiib data scd/-thal
view descript risk reward theme
approv receiv
receiv regulatori approv
peak scd market penetr
receiv approv
receiv fda approv
scd market penetr
fail clinic develop due
receiv regulatori approv
phiia data scd patient demonstr
safety/efcaci larg sampl size
expect
phiib data scd/-thal patient
demonstr safety/efcaci expect
view explan region hierarchi
achiev greater mean
increas hbf phiib
grant acceler approv
note suffici broker suppli
consensu data metric
fail clinic develop
phiib reveal unexpect safeti signal
delay timelin posit data
initi rct data oncolog ind file drive risk/reward
pt deriv dcf use discount rate termin
valu onward base termin growth rate valuat assign credit
rubiu oncolog platform
ew thesi base risk
achiev proof-of-concept oncolog
pose white blood cell therapi
includ broader applic off-the-
shelf approach improv safeti
preclin data encourag date
key risk across oncolog program
deliveri risk especi
program discontinu
commerci strong uptak
commerci oncolog
nsclc immunolog pemphigu
vulgari probabl success po
nsclc pemphigu vulgari
total risk-adjust revenu grow
commerci modest uptak
commerci oncolog
nsclc immunolog pemphigu
vulgari probabl success po
nsclc pemphigu vulgari
total risk-adjust revenu grow
rubiu unabl develop rct
product candid trade cash
 solid tumor dose rst patient
interim data patient
ind ling rct product candid
pipelin drug succeed clinic develop
receiv regulatori approv
poor safeti efcaci would
like caus investor question rubiu rct
posit data competitor could weigh
note suffici broker suppli
consensu data metric
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
efcaci phase studi drive risk/reward
pt deriv discount cash ow analysi assum discount rate
termin growth valu estim us/eu risk-adjust peak revenu
use po mucos pv/mucocutan pv/musk mg
believ cabaletta proprietari
platform yield analog efcaci
compar therapi circumv
safeti shortcom
believ promis
compound demonstr
favor efcaci safeti prole
preclin studi see upsid
potenti acceler approv
believ manag continu
identifi auto-immun diseas
caart technolog appli
musk-caart
caart receiv acceler fda approv
respect similar
risk-adjust peak revenu
program approv phiii
musk-caart
caart receiv tradit fda approv
us/eu risk-adjust peak revenu
fail receiv regulatori
viabil trade cash value-per-share
manufactur valid manufactur support clinic
program
 mucos pv irb approv phi trial
musk-caar musk mg conrmat target engag
initi ind enabl studi
demonstr favor safeti low
vivotarget engag
conrmedpreclin musk-caart
compound move clinic test
succe clinic develop
achiev high market penetr
poor efcaci would like caus investor
question valu platform
unexpect safeti signal pv trial would
like caus investors/regul question
risk-benet ratio lower po
delay timelin posit data
note suffici broker suppli
consensu data metric
note suffici broker suppli
consensu data metric
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
note suffici broker suppli
consensu data metric
transcon pipelin drive share
deriv pt discount cash ow analysi assum wacc
termin growth rate revenu driver model transcon hgh pth
transcon game chang long-act
transcon game chang long-act
therapeutictechnolog util
proprietari transcon technolog
compani abl develop drug
alreadi proven target thu reduc
risk associ develop howev
product
transcon allow substanti
competit advantag includ
conveni dose potenti improv
deeper penetr transcon hgh pth
deeper penetr transcon hgh pth
adopt transcon
commerci product driven
differenti risk-benet prole
project launch therapi
pediatr larg drive valuat
predict drug gain use adult
assum transcon pth
would launch
transcon pth fail launch hgh
transcon pth fail launch hgh
revenu pth
hgh gain modest adopt
file bla/maa transcon hgh pediatr ghd
file ind transcon oncolog asset
phii path forward data transcon pth
phiii foresight trial transcon hgh treat aduklt
ghd expect begin enrol later year
six-month data phii path forward trial transcon
primari driver ascendi transcon
success pipelin candid increas
investor condenc transcon platform
contribut greater overal valu
view explan region hierarchi
clinic data exce expect lead
upsid
regulatori clinicalhurdles/failur
impact transcon hgh transcon pth
investor lose condenc platform valu
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
cost expens
product revenues/royalti
revenu
net loss attribut common stockhold
cash equival
properti equip net
invest associ
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
revers non-cash consider regard revenu
revers share profit/ loss associ
revers financ incom
revers financ expens
revers tax charg
chang oper asset liabil
flow gener from/ use oper
net provid use oper activ
flow invest activ
acquisit properti plant equip
net use invest activ
flow financ activ
proce exercis stock option equiti
capit increas
effect fx translat
chang equival
equival begin year
equival end year
attract lentivir gene therapi platform drive valu
deriv pt discount cash ow analysi assum wacc
termin growth rate revenu driver model risk adjust sale
fabri diseas gaucher diseas market well underli gene therapi platform
gene therapi compani
gene therapi compani
therapi lysosom storag diseas
therapi lysosom storag diseas
fabri diseas phii trial avr-
gaucher diseas
cysteinosi recent enter clinic
pomp pre-clin
steeper ramp fabri gaucher
steeper ramp fabri gaucher scenario
assum rst revenu
risk adjust
launch
adjust sale pomp cystinosi
fabri gaucher drive valu
fabri gaucher drive valu scenario
assum rst revenu
launch risk
adjust cystinosi launch
risk adjust
program fail valu cash
program earliest
potenti approv primari driver
valuat gaucher diseas
also key driver
view explan region hierarchi
updat data gaucher diseas
updat data fabri diseas
updat data cystinosi
first patient dose trial gaucher
diseas depend hospit dynam allow
clinic data exce expect
lead upsid versu number
potenti addit new inid
poor clinic data thati detriment share
sinc lsd establish market
standard care product like
higher bar success
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
cost expens
good sold
net incom common sharehold
prepaid expens current asset
properti equip net
defer revenu net current p\ortion
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
prepaid expens asset
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas market secur
sale matur market secur
net use invest activ
flow financ activ
proce exercis stock option equiti
proce issuanc common stock
effect exchang rate
chang equival
equival begin year
equival end year
market secur end year
deriv pt discount cash ow analysi assum wacc
termin growth rate revenu driver model ayvakit pralsetinib blu-
ayvakit key valu driver blueprint
ayvakit key valu driver blueprint
drug approv pdgfra exon
fourth-lin gist gist
potenti believ drug
would also ultim approv
aggress indol sm
pralsetinib appear promis though
competit dynam could well impact
therapi long-term prospect earli
data pralsetinib show tki
deeper penetr ayvakit
deeper penetr ayvakit assum
deeper penetr forayvakit line
therapi kit driven gist form
sm well higher expect
pralsetinib
launch pdgfr resist gist
kit gist kit driven
gist project launch
ofpralsetinib
appli risk adjust
assum ayvakit use pdgfr
resist gist popul
otherayvakit indic pralsetinib
unapprov
submit nda pralsetinib ret-mut mtc previous
treat approv multi-kinas inhibitor
submit eu pralsetinib ret-mut nsclc
fda decis avapritinib gist may pdufa
report data phiii voyag trial avapritinib
primari driver blueprint avapritinib
kit pdgfr mutant gist well sm
view explan region hierarchi
research highest favor quintil
pipelin drug exceed expect clinic
sale ayvakit higher project
clinic failur ayvakit pralsetinib andblu-
due lack efcaci emerg safeti
earlier stage pipelin fail advanc
collabor yield viabl product
note suffici broker suppli
consensu data metric
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
cost expens
product revenues/royalti
net incom loss continu oper
cumul dividend convert prefer share
net loss attribut common stockhold
cash equival
prepaid expens current asset
properti equip net
current portion defer revenu
accru expens current liabil
accumul comprehens incom loss
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas short-term invest
matur short-term invest
net use invest activ
flow financ activ
proce issuanc common stock
net proce issuanc convert prefer stock
proce lt debt
effect fx translat
chang equival
equival begin year
equival end year
equival end year ex restrict cash
market secur end year
regulatori clariti viaskin peanut drive risk/reward
deriv pt dcf base forecast dbv peanut allergi product
candid viaskin peanut use discount rate termin growth rate
equal-weight
gener mix phiii top line prole
manag subsequ pull back
bla viaskin peanut follow
issu highlight fda bla
subsequ resubmit accept
fda howev fda recent
rais question time regard
efcaci relat adher
viaskin peanut patch feedback
result cancel adcom
previous schedul viaskin peanut
may management work provid
addit data fda review
bla path forward investor remain
modest uptak viaskin peanut
modest uptak viaskin peanut
probabl success viaskin peanut
probabl success viaskin peanut
adjust global sale viaskin
milk viaskinegg commerci
gener aggreg peak
sale
modest uptak viaskin peanut
modest uptak viaskin peanut
probabl success viaskin peanut
probabl success viaskin peanut
bla bla viaskin peanut launch late
 eu
gener risk-adjust global
salesbi contribut viaskin
milk viaskin egg
regulatori failur viaskin peanut
commerci viaskin milk and/or
viaskin egg share trade cash
action date viaskin peanut bla
regulatori progress viaskin peanut bla
view explan region hierarchi
regulatori clariti appear near-term
lesscompetit pressurein peanut allergi
space anticip
delay obtain regulatori clariti
greater expect competit
note suffici broker suppli
consensu data metric
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
pt deriv dcf use discount rate termin growth rate
beyond valu tazemetostat program
tazemetostat promis therapi
tazemetostat promis therapi
like approv epitheliod
sarcoma es earli follicular
lymphoma fl end year
drug broad applic
hematolog cancer potenti
applic solid tumor well
tazverik approv ramp well
tazverik approv ramp well
assumestazverik launch es
fl strong uptak line
therapi
tazverik launch strength later
tazverik launch strength later
line assumestazverik launch es
fl assum bulk
usag fl come later line therapi
tazverik approv fl
tazverik approv fl
indic compani valu cash
initi parp combo studi platinum-resist tumor
small-cel lung tnbc ovarian
potenti approv tazverik fl june
primari driver tazemetostat launch
es regulatori process fl
view explan region hierarchi
research highest favor quintil
posit clinic data combin
therapi new indic could lead
new therapi could emerg pipelin
provid opportun
fda approv wild type fl
data suggest tazverik might
effect combo drug
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
cost expens
product revenues/royalti
oper expens
equival
prepaid expens current asset
properti equip net
current portion defer revenu
accru expens current liabil
current portion capit leas oblig
capit leas oblig net current portion
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas short-term invest
proce sale short-term invest
net use invest activ
flow financ activ
proce public offer common stock net commiss
proce stock option exercis
issuanc share employe stock purchas plan
net proce issuanc prefer stock
proceeds/pay lt debt
payment capit leas oblig
payment stock offer cost
chang equival
equival begin year
equival end year
market secur end year
epidiolex ramp drive gw share
pt deriv dcf use discount rate termin growth rate
beyond valu program cannabinoid base therapi
gw market leader medic
applic cannabis-rel
intervent sativex approv
eu epidiolex approv fda
 transfer schedul
june food drug
cannabidiol cbd oral solut
treatment seizur two rare
sever form epilepsi lennox-gastaut
syndrom dravet syndrom posit
phiii data could lead tuber sclerosi
complex ad label
believ epidiolex would wide
use treatment refractori
epilepsi on-label off-label
well label indic dravet
lenox-gastaut strong label use
epidiolex ramp slower expect
epidiolex ramp slower expect
assum drug ramp well label
indic less steepli anticip
off-label use minim
open label studi cbdv treat autism
phiib trial cbd thc schizophrenia
data one program cbdv
initi phiii trial nabiximol ms spastic
fda approv epidiolex expect juli
sale ramp epidiolex primari
driver share valu
view explan region hierarchi
label use exce expect lead
cannabi base therapi posit clinic
data new indic
gwph stock volatil stock
inuenc heavili quarterli epidiolex
sale perform well broader cannabi
physician hesit prescrib label
discontinu higher anticip
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
cost expens
sale
interest incom
equival
trade receiv asset
properti equip net
trade payabl
trade payabl
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
depreci properti plant equip
chang oper asset liabil
trade receiv asset
trade payabl defer revenu
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas intang asset
net use invest activ
flow financ activ
proce exercis share option
proce new equiti issu
effect foreign exchang rate chang cash cash equival
chang equival
equival begin year
equival end year
despit deep pipelin spinraza still driver
pt deriv dcf use discount rate termin growth rate
beyond valu ioni advanc proprietari antisens oligonucleotid
uw ioni
uw ioni antisens may
promis drug develop platform
underweight ioni believ
spinraza impress highli
success drug chang
competit dynam could
risk furthermor compani
deep pipelin yet comfort
later stage assetsand
theirpotenti success
driven revenu upsid across lead
driven revenu upsid across lead
rapid growth thrombocytopenia
concern physician patient
allow tegsedi achiev stronger
growth appli modest pipelin valu
drug includ ionis-fxirx ionis-
apociii-lrx ionis-apo -lrx ionis-
spinraza still driver despit tegsedi
spinraza still driver despit tegsedi
approv assum spinraza primari
launch limit appli modest
pipelin valu drug includ
apo -lrx ionis-httrx
ioni unabl launch addit product
ioni unabl launch addit product
base case scenario assum
spinraza sale fall short expect
commerci challeng emerg
respect platform pipelin drug
spinraza blockbust treatment
type sma develop candid
like increas focu late stage asset
matur pipelin
view explan region hierarchi
research highest favor quintil
neg news ow pipelin candid
could lead share depreci
emerg safeti signal associ
data compet program could impact
risk ioni pipelin
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
report clinic proof-of-concept result six
rele waylivra nda us year
initi phiii partner akcea akcea-apociii-lrx
posit news ow pipelin candid could
lead share appreci
stronger expect sale perform
spinraza tegsedi would benet share
licens royalti revenu
cost expens
product revenues/royalti
net incom loss attribut akcea
net incom ioni
non-gaap net incom ioni
cash equival
prepaid expens current asset
properti equip net
current portion long-term oblig
defer revenu net current portion
accumul comprehens incom
non-controlling interest akcea
total liabil sharehold equiti
adjust reconcil net loss net cash use oper activ
depreci amort
chang oper asset liabil
pre-paid expens asset
accru expens
net cash provid use oper activ
purchas properti plant equip
purchas market secur
sale matur market secur
net cash use invest activ
proce exercis stock option equiti
proce issuanc common stock
proce issuanc debt
net cash provid financ activ
chang cash cash equival
cash equival begin year
cash equival end year
market secur end year
jaka perform late-stag pipelineprogress drive risk/reward
deriv price target discount cash ow analysi factor explicit
revenu project use discount rate termin growth
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
jaka sale surpass upper rang
jaka sale surpass upper rang
perform ruxolitinib cream
perform ruxolitinib cream
tafasitamab success dlbcl
tafasitamab success dlbcl
jaka sale peak total
revenu ruxolitinib cream
gener peak sale
across vitiligo atop dermat
tafasitamab gener total contribut
guidanc coupl strong pipelin
guidanc coupl strong pipelin
realiz jaka sale
manag long-term guidanc
peak total revenu
approv strong uptak
ruxolitinib cream vitiligo atop
dermat aggreg peak sale
tafasitamab gener total
contribut
overweight base
defens base busi valu provid
jaka mpnsand gvhd combin
option provid late-stag
pipelin key asset includ topic
jak inhibitor ruxolitinib cream
dlbcl believ investor expect
head key mileston
modest result nd risk/reward
skew upsid
jaka sale manag
jaka sale manag
guidanc modest royalti revenu
guidanc modest royalti revenu
sale peak royalti revenu
peak iclusig sale
aggreg peak pipelin revenu
phiii data ruxolitinib steroid-refractori cgvhd
updat phii data pemigatinib bladder cancer
regulatori approv rux cream ad
phiii data vitiligo
clinic regulatori progress antibodi
data pemigatinib bladder cancer
detail jaka life cycl extens program
view explan region hierarchi
research highest favor quintil
greater pipelin realiz base case
project includ addit busi
long-term jaka sale perform
regulatori failurefor ruxolitinib cream ad
slow launch assum approv
clinic and/or regulatori failur tafasitamab
failur and/or minim success earlier-
stage program like pemigatinib
note suffici broker suppli
consensu data metric
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
termin growth rate
ew ironwood
ew ironwood equal-
weight ironwood expect linzess
growth like maintain stabl growth
compani data
readout refractori gerd
abdomin pain await
addit data ad
therapi project
linzess isth domin player ib cic
linzess isth domin player ib cic
market linzess prefer treatment
ib cic domin
over-the-counter therapi push past
grow share ib cic market beat
brand player make
headway expens over-the-counter therapi
net sale push past
linzess slow ibs-c cic market slow
tough competit take share
present data phii patient
subtyp ib abdomin pain
key revenu driver model linzess
view explan region hierarchi
research highest favor quintil
versu expect
one compani pipelin drug could achiev
superior data lead us increas
expect regard potenti
downsid versu expect
ration fall short
expect lead downsid
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
million per share basi indic
commerci cost expens
net profit loss sale linzess
ironwood share net profit loss
revenu
revenu
interest expens
interest invest incom
provis incom tax
net incom loss disc oper
million per share basi indic
cash equival
prepaid expens current asset
total liabil stockhold equiti
properti equip net
accru research develop cost
current portion long-term debt
current portion leas oblig
long-term liabil discont oper
accumul comprehens incom
illion per share basi hen indic
incom loss discontinu oper
incom loss continu oper
depreci amort
loss gain dispos properti equip
impair loss long-liv asset
remeasur forward purchas contract
write-down inventori net realiz valu
loss facil subleas
accret discount premium invest secur
chang fair valu note hedg warrant
chang fair valu convert note hedg
chang oper asset liabil
chang inventori
prepaid expens current asset
account payabl accru expens
accru research develop cost
net cash use oper activ disc op
net cash use oper activ
purchas available-for-sal secur
sale matur available-for-sal secur
purchas ppe
proce sale properti equip subsidiari
proce sale subsidiari
net cash use invest activ
proce issuanc prefer stock net issuanc cost
proce share issuanc
proce exercis stock option stock purchas plan issuanc common
proce sale noncotrol interest subsidiari
tax benefit stock option
disburs repurchas common stock
proce issuanc note payabl
proce issuanc note hedg warrant
purchas convert note hedg
associ issuanc note payabl
payment borrow capit leas oblig
princip payment debt
net cash provid financ activ
increas cash cash equival
equival begin year
equival end year
margituximab updat dart bispec platform driver
rate beyond valu macrogen advanc therapeut program
underweight macrogen
underweight macrogen though
margetuximab could approv base
inabl differenti os
lower expect respect
target enoblituzumab think
could offer greatest util combin
checkpoint inhibitor would
like see data increas
better uptak margituximab
better uptak margituximab
sale treatment breast
enoblituzumab achiev success
trial launch treatment
valu potenti dart platform
margetuximab peak
margetuximab peak
margetuximab struggl achiev modest
success refractori breast cancer patient
revenu enoblituzumab includ
pipelin valu potenti dart
failur commerci proprietari
failur commerci proprietari
partner program macrogen
enoblituzumab gener product relat
dene potenti registr path otetuzumab
present data dart come
data margetuximab phii/iii mahogani studi
like odac panel margetuximab treat late line
possibl approv margituximab breast cancer
clinic data dart bispec antibodi
beyond
posit updat margetuximab head
support valuat
clinic updat includ potenti
view explan region hierarchi
margetuximab util could greater
posit clinic data pipelin candid
could improv prospect lead stock
margetuximab might approv
dart platform could associ
safeti signal downgrad potenti
note suffici broker suppli
consensu data metric
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
pt deriv dcf use discount rate termin growth rate
beyond valu nabriva antibiot program
xenletaachiev strong ramp inpati
xenletaachiev strong ramp inpati
outpati set
outpati set xenleta achiev
peak sale contepo
reach sale
expect gener might enter market
xenleta get use commun set
xenleta get use commun set
risk adjust xenleta sale expect
reach contepo
approach risk adjust sale
equal-weight nabriva
equal-weight nabriva
believ xenleta contepo potenti
highlight antibiot market
challeng earli run rst class
xenleta difculti gain uptak
lead shift market strategi
contepo rst-in-class epoxid
could potenti approv cuti
although opportun somewhat modest
also given current pandem time
approv could question despit
stock valu cash
stock valu cash
fda decis expect pdufa date
key valu driver commerci ramp
lefamulin contepo
view explan region hierarchi
expect lead upsid
contepo might approv
sale ramp either lefamulin contepo
could challeng
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
research premium grant revenu
cost expens
product revenues/royalti
cash equival
prepaid expens current asset
properti equip net
accumul comprehens incom loss
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
non-cash incom net
chang oper asset liabil
accru expens liabil
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas term deposit
proce sale available-for-sal secur
transact
net use invest activ
flow financ activ
proce exercis stock option equiti
proce issuanc common stock
proce lt debt
effect fx translat
chang equival
equival begin year
equival end year
market secur end year
biontech acquisit neon drive risk/reward
price target base announc acquisit valu
acquisit neon
close announc
premium deal valu
competit bid lead increas
acquisit close announc
acquisit close
ntgn trade slight premium
cash value-per-share base investor
expect continu strateg interest
neon
acquisit close
view explan region hierarchi
competit bid process develop prior
close acquisit biontech
key risk acquisit
close close signicantli later
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
us eu row dcf base explicit revenu project
free cash ow growth rate use
remain equal-weight base key
unknown risk associ launch
commerci pressur observ
await addit clariti launch metric
need physician support
factor xa antidot consider
bleed signic potenti
devast complic anticoagul
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
andexxa becom standard care
andexxa becom standard care
forecast period
modest uptak andexxa
modest uptak andexxa andexxa
gener global peak sale forecast
period
slow ramp andexxa
slow ramp andexxa assum
andexxagener global sale
base low dcf valu
gener scenario assign cash
value-per-share bear case
trajectori andexxa sale
eu
view explan region hierarchi
andexxa launch could inect near-
term drastic anticip
andexxa launch could continu
sluggish drug may end
obtain signic uptak physician
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
program osteoporosi oncolog drive risk/reward
deriv pt discount cash ow analysi assum wacc
termin growth rate revenu driver model tymlo pen
abaloparatid patch osteoporosi well elacestr breast cancer
overweight radiu
encourag trajectori date
osteoporosi drug tymlo lead us
believ tymlo captur sizeabl
portion anabol market
tymlo abaloparatid patch could
differenti product osteoporosi
market current anticip launch
given top line data on-going
phiii studi expect
elacestr gener encourag
data date path forward remain
unclear management aim nd partner
asset result assign molecul
likelihood success model
ww sale tymlo pen
abaloparatid patch
valu illustr partnership
radiu receiv royalti
ww sale tymlo pen
abaloparatid patch
likelihood success assign
valu illustr partnership
radiu receiv royalti
ww sale tymlo pen
abaloparatid patch
respect elacestr
success reach market
time launch price potenti forteo
updat possibl elacestr partnership
view explan region hierarchi
management nd partner elacestr sooner
expect
commerci subsequ pressur
forteo competitor program
inabl success develop
commerci abaloparatid patch
inabl partner elacestr time
manner lead minim valu contribut
asset near-to-mid term
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
pt deriv dcf use discount rate termin growth rate
beyond valu rhythm program orphan genet disord obes
ow rhythm
ow rhythm setmelanotid
intrigu therapi relat ultra
orphan obes rhythm posit
phiii date pomc lepr decienc
sould rst fda approvallat
year second half posit
phiii data bb alstrom syndrom
materi add opportun
setmelanotid approv launch
pomc null lepr decienc
setmelanotid data bardet-biedl
syndrom bb alstrom suggest
drug could exceed expect
indic rais condenc
setmelanotid like reach market
setmelanotid like reach market
pomc null lepr decienc
pomc null lepr decienc data
bardet-biedl syndrom largest valu
driver model appear promis
incorpor alstrom risk
setmelanotid fail reach market
setmelanotid fail reach market rhythm
trade cash
provid updat sequenc effort rel patway
setmelanotid
provid updat clinic develop once-weekli
formul setmelanotid
ind prader-willi syndrom ghrelin o-
data phii basket pathway heterozyg studi
strati lof variant addit data trial
submit ema setmelanotid pomc lepr
valuat driver perceiv clinic
regulatori risk setmelanotid pomc
syndrom bb alstr syndrom pomc
view explan region hierarchi
sale small pomc lepr indic
exceed expect approv
posit data addit mutat
suggest expand market opportun
bbs/alstrom phiii trial fail present
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
cost expens
product revenues/royalti
net incom loss continu oper
cash equival
prepaid expens current asset
properti equip net
due relat parti
accru expens current liabil
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas short-term invest
sale short-term invest
net use invest activ
flow financ activ
proce issuanc common stock
net proce issuanc seri convert prefer stock
proce lt debt
proce exercis stock option equiti
effect fx translat
chang equival
equival begin year
equival end year
market secur end year
discount rate drug discov busi
risk adjust proprietari
softwar grow upper teen pipelin
discount rate drug discov busi
risk adjust proprietari
combin multipl analysi softwar npv drug discoveri
view excit
compani two distinct high-growth
busi softwar busi high-
growth potenti transform
offer provid efcienc
pharmaceut biotechnolog player
drug discoveri process drug
discoveri busi taken
core compet use physic
formolecular simul develop
pipelin equal-weight due lack
clariti street view valuat
time sinc compani launch
share overli volatil
unpredict subject substanti price
swing volatil creat undo risk
us sidelin
view descript risk reward theme
ind potenti led year-end
primari driver softwar busi
increas spend larger
pharmaceut biotechnolog spender
primari driver drug discoveri
busi advanc proprietari
view explan region hierarchi
pharma/biotechspend softwar
pharma/biotechspend software-
bigger move pharma/biotech toward
pipelin risk setback pipelin
 relat disruptions-stay home
ordersdu pandemiccould
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
softwar product servic
revenu
research develop
 sale
sg sale
income/ loss oper
net incom loss schroding
prepaid expens current asset
properti equip net
defer revenu net current p\ortion
accumul comprehens loss
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
equiti invest
chang oper asset liabil
prepaid expens asset
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas equiti invest
distribut equiti invest
purchas market secur
proce market secur
net use invest activ
flow financ activ
proce exercis stock option equiti
proce issuanc common stock
effect exchang rate
chang equival
equival begin year
equival end year
market secur end year
success develop entinostat hr breast cancer drive risk/reward
equal-weight syndax
develop class hdac entinostat
near-term compani stock
leverag outcom phiii
trial hr breast cancer although
menin-llr program intrigu
condenc entinostat/checkpoint
inhibitor combin wane
somewhat howev could
eventu path forward inam tumor
nsclc melanoma
assum entinostat achiev rapid
assum entinostat achiev rapid
uptak hr bc
uptak hr bc assum combin
hormon therapi hr breast
assum modest uptak hr bc
assum modest uptak hr bc assum
modest hr her- breast cancer sale
assum entinostat fail achiev
assum entinostat fail achiev
sufcient clinic result hr her-
sufcient clinic result hr her-
phii expans cohort cgvhd
data phi/ii open-label augment
final overal surviv analysi entinostat pivot
hr breast cancer
top-line data cgvhd
stock valuat highli link success
phiii trial
view explan region hierarchi
posit os analysi may
studi would lead dramat upsid
posit data pipelin product
expect regard therapi
neg safeti efcaci data
therapeut program develop
note suffici broker suppli
consensu data metric
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
cost expens
product revenues/royalti
incom loss attribut stockhold
net incom loss attribut common stockhold
equival
prepaid expens current asset
properti equip net
defer revenu net current portion
total liabil sharehold equiti
adjust reconcil net loss net cash use oper activ
chang oper asset liabil
pre-paid expens asset
accru expens
net cash provid use oper activ
purchas properti plant equip
purchas market secur
sale matur market secur
payment asset acquisit
net cash use invest activ
proce exercis stock option equiti
proce issuanc common stock
proce payment issuanc debt
net cash provid financ activ
chang cash cash equival
cash equival begin year
restrict includ line item
cash equival end year
market secur end year
valuat base manag boxr pipelin option
solid tumor studi attck-
serv basi
pipelin consist
preclin molecul
ind ling expect proof-
valid data expect near-
term wecurr valu umrx base
realiz valu boxr repres
bull-cas driver dcf await initi
proof-of-concept data boxr
realiz risk-adjust valu
boxr platform either independ
develop partnership
base case
cash burn greater
anticip base case
manag cash balanc
potenti strateg interest
view explan region hierarchi
strateg interest umrx
rapid develop boxr platform
base case assum
burn aggress
anticip base case
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
dasiglucagon glepaglutid driver
pt deriv dcf use discount rate termin growth rate
strong pipelin support ow rate
strong pipelin support ow rate
view zealand strong pipelin
led two therapi glepaglutid
dasiglucagon improv version
standard care drug
dasiglucagon could better offer
dasiglucagon could better offer
us sever hypoglycemia market
us sever hypoglycemia market
dasiglucagon rescu medic
sever hypoglycemia repres
conveni offer current market
glepaglutid next-gen
glepaglutid next-gen
could improv prole
could improv prole
glepaglutid enhanc stabil
extend half life compar current
market productsand allow drug
preformul
superior prole product differenti
sb hypoglycemia respect
lead acceler uptak versu current
standard care
dasiglucagon glepaglutid
dasiglucagon glepaglutid
competit pipelin asset
approv view competit
standard care
dasiglucagon glepaglutid fail reach
initi phib multiple-ascend dose safeti
toler trial
submit dasiglucagon
glepaglutid dasiglucagon successshould
view explan region hierarchi
posit data pipelin could lead
addit upsid stock
fail clinic trial pipelin candid
dasiglucagon glepaglutid
potenti need rais dilut equiti
note suffici broker suppli
consensu data metric
note suffici broker suppli
consensu data metric
note suffici broker suppli
consensu data metric
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
dkk million
product revenues/royalti
nsdq zeal dkk million
prepaid expens current asset
properti equip net
total liabil sharehold equiti
nsdq zeal dkk million
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
chang work capit
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas secur
purchas invest
transfer to/from restrict cash relat royalti bond
transfer restrict cash royalti bond interest payment
net use invest activ
flow financ activ
proce issuanc share relat exercis warrant
proce issuanc common stock
repay royalti bond
effect exchang rate
chang equival
equival begin year
equival end year
market secur end year
pt deriv discount cash ow analysi assum discount rate
full pulsar data strong studi
full pulsar data strong studi
investig suggest bull case
assum probabl success po
sotatercept pah addit increas
po non-transfus depend beta
thal increas
launch trajectori transfusion-
depdend beta thal better-than-
revenu pah
revenu pah assum
po sotatercept
overweight rate base
increas condenc sotatercept
play meaning role pulmonari arteri
hypertens pah top standard
care remain posit luspatercept
see greater upsid potenti
share sotatercept given better
econom acceleron
luspatercept drug
novel pathway show benet top
standard care
view descript risk reward theme
full pulsar data disappoint
full pulsar data disappoint
luspatercept success follow-on
luspatercept success follow-on
indic bear case assum
lower condenc approv
sotatercept addit model slower
launch trajectori luspatercept
beta thal md
ema decis md beta-th
data phase spectra studi
top-line luspatercept phase beyond data non-
potenti approv luspatercept md
spectra data pah
phase part data cmt
research highest favor quintil
better-than-expect pulsar data full
disappoint pulsar data full
fail cmt
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
pt deriv discount cash ow analysi assum discount rate
equal-weight aprea
develop cancer therapi reactiv
mutant posit
compani believ share fulli
valu follow strong perform
sinc ipo result remain
sidelin look better entri point
ahead phase data
date phase data two studi
indic improv respons rate apr-
azacitidin histor azacitidin
md aml patient
compani focus initi md
aml evid apr-
could effect treat solid
higher probabl success po
higher probabl success po
assum higher po md
mds/aml post-transpl mainten
r/r aml follow posit
posit phase data md
posit phase data md assum
peak us market share
mutant md md post-
transplant mainten
mutant aml adjust use
po respect
platform reactiv mutant fail
platform reactiv mutant fail
aprea unabl advanc product
candid trade cash value-per-share
final french phase data mds/aml
phase data md
phase data md
better-than-expect phase data md
disappoint phase data md
lack advanc early-stag pipelin
potenti litig patent
competit mds/aml therapi
note suffici broker suppli
consensu data metric
note suffici broker suppli
consensu data metric
note suffici broker suppli
consensu data metric
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
omecamtiv mecarbil drive risk/reward
pt deriv discount cash ow analysi use discount rate
overweight
area signic unmet need includ
heart failur hypertroph
omecamtiv mecarbil om
shown improv cardiac function shift
patient toward normal eject
ventricular wall stress decreas heart
view descript risk reward theme
greaterpo posit om
greaterpo posit om
data bull case assum greater
po posit galactic-hf data om
encourag phase data
om reach market
om reach market model
peak unadjust ww om sale
adjust use po om
galactic-hf studi disappoint
galactic-hf studi disappoint
product candid advanc
product candid advanc
cytokinet unabl advanc
product candid trade cash
data cohort redwood-hcm
begin reldesemtiv phase studi al
faster-than-expect advanc pipelin
safeti signal aris
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
pt deriv discount cash ow analysi assum discount rate
equal-weight believ
expect cabozantinib rcc
larg price share think
bar checkmat high
expect sale growth
gradual
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
greater peak market share rcc
greater peak market share rcc
hcc hcc bull case assum peak us
market share translat
peak sale addit
assum peak us market share rcc
share translat
peak sale rcc
expect gradual launch
expect gradual launch
model peak us market share
translat peak us sale
rcc assum declin us
market share peak market share
translat peak us
lower long-term market share rcc
lower long-term market share rcc
share declin patent
expir rcc reach
share rcc
checkmat data rcc
phase data dtc
mcrpc nsclc
rcc
china india
view explan region hierarchi
research highest favor quintil
better-than-expect data later stage
combin studi cabozantinib
faster-than-expect develop result
earlier ling sizeabl indic
acquisit later-stag asset announc
note suffici broker suppli
consensu data metric
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
mavacamten danicamtiv drive risk/reward
pt deriv discount cash ow analysi assum discount rate
termin growth rate
overweight myokardia
well-den subgroup unmet medic
promis phase data
gener lead asset mavacamten
obstruct non-obstruct
higher probabl success po
higher probabl success po
mavacamten danicamtiv
mavacamten danicamtiv assum
higher po ohcm
nhcm dcmwith posit data
assum peak us market share
assum peak us market share
ohcm nhcm dcm
ohcm nhcm dcm
adjust use ohcm
po nhcm po dcm
unabl advanc product candid
trade cash value-per-share
top-line mavacamten phase explorer-hcm data ohcm
regulatori updat nhcm
full phase data danicamtiv dcm
present full mavacamten phase explorer-hcm
phase data healthi volunt hcm
research highest favor quintil
data explorer-hcm better-than-
data danicamtiv phase present
better-than-expect
phase data better-than-
disappoint efcaci and/or safeti data
concern danicamtiv safeti data
prevent advanc subsequ studi
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
pt deriv discount cash ow analysi assum discount rate
overweight thesi driven
think possibl achiev
partnership voyag offer
exposur larg market
pipelin candid like crinecerfont
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
assum peak market share
vy-aadc themarket
us ingrezza sale td
us ingrezza sale td
assum peak us market share td
slower growth td sale
slower growth td sale bear case
assum lower peak us market share
ingrezza td translat
peak sale addit
assum vy-aadc abl reach
present vy-aadc result trial
present vy-aadc result trial
potenti approv orilissa uterin fibroid
phase data adult endo
potenti approv opicapon parkinson
potenti opicapon approv launch
vy-aadc result trial
year vy-aadc result trial
view explan region hierarchi
research highest favor quintil
vy-aadc pivot studi enrol faster
expect better-than-expect long-term
teva sign aggress contract austedo
vy-aadc pivot studi enrol
expect safeti signal aris long-term
data support strong durabl
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
pt deriv discount cash ow analysi assum discount rate
overweight nextcur
dene subgroup unmet medic
phase data provid evid
addit program pipelin
candid find-io platform
provid opportun upsid
enter clinic advanc develop
higher po
higher po assum higher
probabl success po peak share
reach market
reach market
share
adjust use po
immunotherapi platform fail
unabl advanc product candid
trade cash value-per-share
disappoint efcaci and/or safeti data
disappoint efcaci and/or safeti data
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
pt deriv discount cash ow analysi assum discount rate
higher probabl success po pd-
higher probabl success po pd-
gba gba assum higher po
ngd pd-gba posit initi data
addit assum greater peak market
reach market ngd
reach market ngd
pd-gba
pd-gba assum peak us
market share neuronopath
gaucher diseas ngd
parkinson diseas mutat pd-
gba adjust use
overweight prevail compani
dene patient subpopul unmet
preclin data suggest
efcaci safe preclin data
indic glucocerebrosidas gcase
increas glycolipid accumul
reduc motor function improv
-synuclein accumul reduc
de-risk vector track
record safeti efcaci support
approv novartis/avexi zolgensma
infant sma type
provid opportun
upsid enter clinic
advanc develop
gene therapi platform fail prevail
unabl advanc product candid
trade cash value-per-share
interim phase provid data type gd
biomark data phase propel
studi pd-gba
phase data type gaucher diseas
biomark data phase studi
better-than-expect data type gaucher
better-than-expect interim data pd-gba
disappoint efcaci and/or safeti type
disappoint interim data pd-gba
lack advanc early-stag pipelin
note suffici broker suppli
consensu data metric
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
crysvita drive risk/reward
pt deriv discount cash ow analysi assum discount rate
overweight rate base
belief street undervalu
crysvita launch remain strong
potenti upsid greater adopt
adult famili
like ultragenyx third
data
promis condenc
compani continu deepen
diversifi pipelin addit
posit data readout better-than-
posit data readout better-than-
po po
follow subsequ conrmat
posit data support advanc
program phase addit
lead greater peak market share
crysvita mepsevii
adjust revenu addit
peak ww sale crysvita
mepsevii model peak
unadjust ww sale
adjust
sale estim use
po
pipelin product fail bear case
assum lower
probabl success approv
call question mepsevii
crysvita face slower adopt us
data phase expans cohort
begin phase angelman syndrom
data phase prophylact steroid cohort
potenti approv lc-faod pdufa date
view explan region hierarchi
research highest favor quintil
faster-than-expect growth crysvita sale
faster-than-expect advanc earlier
delay approv
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
pt deriv discount cash ow analysi assum discount rate
overweight viela compani
develop treatment autoimmun
inebilizumab clinic de-risk
nmosd follow posit phase data
think like approv mid-
believ inebilizumab like one
favor treatment front-lin
addit
indic inebilizumab provid
opportun upsid
inebilizumab approv nmosd
inebilizumab approv nmosd
quicker ramp launch also
assum higher po pipelin program
mg sjogren
inebilizumab approv nmosd mid-
inebilizumab approv nmosd mid-
adjust use po
fda request addit data result
fda request addit data result
delay approv
delay approv assum lower po
inebilizumab nmo
submit ind begin pivot trial inebilizumab mg
submit ind begin phase trial inebilizumab
phase interim data cutan lupu
potenti approv inebilizumab nmosd pdufa date
potenti approv inebilizumab nmosd
initi launch inebilizumab nmosd
phase interim data cle
research highest favor quintil
launch inebilizumab nmosd better-
delay approv compet
fda approv inebilizumab
nmosd june pdufa date
launch inebilizumab nmosd
slower-than-expect due intens
competit soliri satralizumab off-
lack advanc pipelin product
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
vy-aadc parkinson drive risk/reward
pt deriv discount cash ow analysi assum discount rate
equal-weight rate base
limit clinic catalyst
major valuat driven
vy-aadc parkinson
optimist view vy-aadc
optimist view vy-aadc
scenario assum po greater
market share vy-aadc us eu
vy-aadc us launch
vy-aadc us launch model
unadjust us vy-aadc revenu
voyag receiv prot share
addit risk-adjust sale
gene therapi platform fail bear case
assum voyag unabl advanc
product candid trade
present vy-aadc result trial
present vy-aadc result trial
begin phase vy-aadc pd
vy-aadc result trial
vy-aadc result trial
vy-aadc pivot studi enrol faster
expect result earlier data readout
vy-aadc pivot studi enrol slower
safeti signal aris vy-aadc
longer term data support strong
durabl respons
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
safeti efcaci data ftd-grn drive risk/reward
pt deriv dcf use discount rate termin
growth rate revenu driver model current
model separ given earli stage develop
arecommerci strong uptak
arecommerci strong uptak
bull case valu
product launch
respect captur signic
success commerci
success commerci
base case
valu po
po product launch
begin
overweight thesi base
success commerci
design treat well dene
genet diseas measur biomark
compar neurodegen
probabl success
phi trial healthi volunt
demonstr target engag
provid condenc impact
view descript risk reward theme
fail unabl
commerci trade cash
initi phiii trial ftd patient
phib intercept pom data alzheim diseas patient
phi intercept pom data healthi volunt siglec
phib invok pom data alzheim diseas patient
initi infront phii poc data ftd-pgrn
infront phii data ftd-
pgrnpatient expect
phi pomdata alzheim diseas
patient expect
view explan region hierarchi
research highest favor quintil
efcaci broad ftd subtyp
signal would like caus investor question
valu
reduc efcaci ftd
delay timelin posit data
effect treat
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
ultomiri convers soliri neurolog launch pipelin drive risk/reward
deriv pt discount cash ow analysi assum wacc
termin growth rate revenu driver model pnh sale ahu sale mg
sale nmo sale strensiq sale kanuma sale
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
ahu mg penetr ultomiri
ahu mg penetr ultomiri
succe signic share convers
succe signic share convers
standard care pnh ahu nmo
mg pnh sale
peak ww ahu sale
peak assum strensiq
kanuma continu launch
sale respect
soliri meaning growth pnh ahu
soliri meaning growth pnh ahu
gmg
gmg ultomiri succe modest
solid convers ultomiri long-term
durabl complement franchis
assum gmg nmo meaning
contribut sale assum strensiq
kanuma continu launch
sale respect
see soliri longev incorpor
competit price pressur
equal-weight believ
despit strong execut management consensu
need see greater revenu divers
away franchis
increas termin multipl
believ initi ultomiri execut
strong pnh expect similar
transit ahu see option
subcutan neurolog indic
expect potenti posit
develop pipelin believ
management undertak organ rebuild
compani take time drive new
view descript risk reward theme
kanuma achiev minim sale
kanuma achiev minim sale bear
case assum soliri fail gain label
expans soliri face signic
headwind biosimilar
proprietari competit divers
strensiq kanuma minim
initi phii trial pnh
init phii studi waiha iv
initi limit dose-rang studi ultomiri adult
children hsct-tma
potenti launch pnh ultomiri mg/ml
administr pnh/ahu
ultomiri mg/ml launch pnh
view explan region hierarchi
research highest favor quintil
soliri pnh ahu mg growth could fail
meet expect
strensiq and/or kanuma fail captur market
share convers soliri ultomiri
project
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
safeti efcaci data mg itp pv drive risk/reward
pt deriv dcf use discount rate
termin growth rate revenu driver model
overweight thesi base
success commerci
sever compani develop anti-
fcrn antibodi treatment
autoimmun diseas mani compani
report safeti and/or reduc efcaci
compar
design uniqu ph-
depend bind prole extend
therapeut durabl fewer report
advers event compar compet anti-
diseas indic demonstr
efcaci safeti
demonstr clinic
activ aml
commerci
commerci
strong uptak
strong uptak bull case valu
risk adjust
vari product launch
begin
argenx success commerci
argenx success commerci
base case
valu mg itp pv aml ctcl risk
adjust vari product
launch begin
respect
view descript risk reward theme
fail argenx unabl
commerci argx trade
expect announc indic efgartigimod
culmin phib/ii data aml patient
initi phii trial higher-risk myelodysplast syndrom
cohort gmg efgartigimod
subq efgartigimod
top-line phiii adapt data gmg
submit bla gmg expect
durabl data aml
view explan region hierarchi
phiii data gmg demonstr
differenti safeti efcaci
demonstr efcaci aml
indic
delay timelin posit data
competitor could weigh market
share especi competitor data arriv
new indic prior pivot trial
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
aducanumab tecdera royalti pipelin drive risk-reward
main driver tecdera spinraza ocrevu pipelin
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
limit impact biosimilar signic
limit impact biosimilar signic
margin expans lower discount
margin expans lower discount
pipelin asset assum
peak tecdera sale gener
limit declin
plegridy/avonex franchis
continu tysabri growth
peak sale aducanumab
sale spinraza
sale limit impact
rituxan/gazyva biosimilar
assum peak
tecdera sale gener enter
stabl
tysabri sale
aducanumab sale
probabl success biosimilar
rituxan impact start mainli
off-set grow ocrevu royalti
uw rate base view
risk base busi weigh
spinraza competit rituxan
biosimilar tecdera legal
challeng expect play
risk/high reward option remain
unconvinc data support approv
management track record transform
late-stag limit
expect signic capit
deploy could improv
risk/reward aducanumab fda
view descript risk reward theme
impact pipelin assum
impact pipelin assum
global tecdera sale
loss patent protect
declin plegridy/avonex sale
greater competit
biosimilar rituxan impact start
vixotrigin initi phii trial small ber
natalizumab tysabri phii data epilepsi
aducanumab -amyloid antibodi ling decis
fda
opicinumab data affin trial remitting-relaps
phii/iii trial test nsr-rpgr x-link
assum earli potenti pdufa
data assum late
updat current legal case regard
tecdera district court decis
view explan region hierarchi
research highest favor quintil
aducanumab approv strong sale
spinraza competitor fail make
pipelin success stroke pain follow-on
aducanumab approv
rituxan biosimilar take share quickli
ocrevu lose share ofatumumab
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
rimegep glutam platform valid drive risk reward
deriv pt discount cash ow dcf analysi assum wacc
termin growth rate post main revenu driver model
rimegep episod migrain lesser extent glutam platform orphan
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
robust rimegep uptak episod
robust rimegep uptak episod
migrain commerci
migrain commerci
chronic migrain strong share
chronic migrain strong share
addit neurolog indic
addit neurolog indic
launch acut migrain
platform begin gener revenu
strong share rimegep episod
strong share rimegep episod
migrain modest share addit
migrain modest share addit
neurolog indic glutam
neurolog indic glutam
platform rimegep launch
ex-u commerci
commerci chronic
migrain glutam platform abl
commerci ex-u
equal-weight biohaven lead
larg unmet need acut treatment
migrain phiii data suggest product
could differenti safeti howev
believ valuat reect posit
aspect thu see balanc
signic pipelin driver troriluzol bhv-
gener encourag
data troriluzol achiev
statist signic result phii/iii
result seem trial/ind specic
current see limit read
view descript risk reward theme
pipelin failur rimegep glutam
platform molecul fail develop
process compani trade cash
troriluzol top-line phii/iii data obsess compuls
verdiperstat initi phiii al
launch rimegep acut treatment
migrain next step prevent
treatment migrain
phii/iii troriluzol data treatment
view explan region hierarchi
research highest favor quintil
rimegep approv prevent
treatment migrain take signic
glutam platform demonstr efcaci
broad rang neurolog indic
regulatori hurdl rimegep and/or
minim efcaci prevent treatment
poor safety/efcaci data glutam
platform molecul trigriluzol
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
program al alzheim parkinson bbb platform drive risk/reward
pt base dcf base case forecast parkinson al
alzheim bbb platform discount rate assum termin
growth cash ow
overweight thesi base
condenc manag abil
inect product histor
difcult treat area neurosci
believ manag right
process inect success use
genet target biomark target
engag parallel invest
improv success initi target
repres initi yardstick
opportun greatli expand treatment
mani neurolog disord
greater alzheim market share
greater alzheim market share
success idiopath parkinson
success idiopath parkinson
bull case assum market share
al market share alzheim
share total parkinson
popul alzheim risk-adjust
risk-adjust success alzheim
risk-adjust success alzheim
good probabl success mutat
good probabl success mutat
valu bbb program
valu bbb program
al market share alzheim
share mutat parkinson
bbb program repres total peak
alzheim success mutat
alzheim success mutat
parkinson valu bbb
parkinson valu bbb
program approv al
alzheim approv
peak revenu
etv id initi phi/ii studi hunter syndrom
decid bw initi phii/iii trial
go/no-go decis relat mid-
initi phii/iii trial test either
view explan region hierarchi
research highest favor quintil
program
bbb program achiev efcaci sever
preclin clinic safeti signal
program
inabl advanc program
clinic test due poor efcaci
failur bbb program
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
durabl data wamd drive risk/rew
pt deriv dcf use discount rate revenu
driver model kodiak lead anti-vegf candid retin diseas
commerci multipl
commerci multipl
retin diseas strong uptak
retin diseas strong uptak
launch wet rvo
diabet eye diseas peak
penetr probabl success po
commerci limit set
commerci limit set
retin diseas modest uptak
retin diseas modest uptak ksi-
commerci wet
peak penetr probabl
success po
overweight thesi base
success commerci
sever compani commerci
anti-vegf therapi treatment
retin diseas burden monthli
bimonthli treatment reduc long
design extend therapeut
durabl compar current therapi
phi/ib data demonstr extend
durabl clean safeti prole
view descript risk reward theme
fail kodiak unabl develop
trade cash value-per-share
initi phiii trial dme
initi phiii trial dr without dme
option interim pivot phii dazzl data
direct phib phii interim
initi phiii trial diabet eye diseas
view explan region hierarchi
research highest favor quintil
differenti durabl rang eye
question valu biopolym
increas toxic advanc patient
posit data competitor could weigh
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
deriv pt dcf base forecast mrna base product
candid use discount rate termin growth rate
overweight moderna
compani taken industri
approach develop mrna base
therapeut rapidli gener
broad pipelin program
enter clinic develop
platform diversi scalabl
compar competitor valid
broad partnership merck
signal gener preclin
earli clinic studi date indic
mrna therapeut activ
across wide varieti modal
indic rang prophylact
strong share pipelin
strong share pipelin
program bull case valu
program base case well
oncolog relaxin heart failur
fabri program risk adjust vari
product launch begin
success pipelin
success pipelin
hmpv pcv kra cancer
vaccin program vegf-a rare
diseas program mma pa pku risk
adjust vari
product launch begin
view descript risk reward theme
platform fail product
technology/clinical/regulatori failur
therefor gener revenu moderna
share trade cash value-per-share
phii data test pcv keytruda compar
paus initi phi/ii trial treatment
clinic start complet dose escal monotherapi
phi data hv niaid sponsor
addit earli clinic stage data
intratumor i/o local regen
therapeut modal expect
nomin addit drug candid
view explan region hierarchi
research highest favor quintil
meet timelin continu expand
launch vaccin multipl indic
write-off subsequ readout across
delay abil gener
stronger expect competitor data
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
eylea dupix oncolog pipelin drive risk-reward
deriv pt discount analysi use wacc
termin growth rate
ew regeneron believ
potenti upsid factor success
libtayo nsclc earli stage
bi-spec pipelin off-set potenti
risk intern refer price
pressur eylea
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
strong dupix growth success
strong dupix growth success
oncolog pipelin limit eylea
oncolog pipelin limit eylea
competit biosimilar brand
competit biosimilar brand
competit assum us
eylea row eylea
sarilumab us sale
us dupilumab sale
dupix growth multipl indic
dupix growth multipl indic
us eylea row eylea
us dupilumab sale
eylea pressur limit dupix growth
eylea pressur limit dupix growth
outsid core indic assum
outsid core indic assum
us eylea row eylea
us praluent
modest row praluent sale
dupilumab sale
garetosmab submit patient fibrodysplasia
initi phii trial gener lipodystrophi
praluent submit homozyg famili
eylea initi phiii trial retinopathi prematur
dupix phiii data copd
driver includ impact potenti eylea
competit updat dataset
oncolog pipelin growth dupix
view explan region hierarchi
research highest favor quintil
signic implement part
signic eylea competit sale
signic penetr libtayo nsclc
eylea face brand biosimilar competit
take signic share
oncolog pipelin fail perform
dupix atten earlier expect
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
primari risk/reward driver
pt deriv dcf use discount rate termin growth rate
beyond valu neurolog program
brexanolon approv asset
clear unmet need form basi
valuat clear upsid
potenti much broader
depress bipolar disord insomnia
pipelin broad continu offer
new drug extens effort target
gaba nmda
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
brexanolon launch steep
brexanolon launch steep
trajectori provid bulk
valuat strong launch mdd
bipolar insomnia
brexanolon launch modest
brexanolon launch modest
trajectori provid bulk
valuat launch mdd bipolar
insomnia
approv modest launch
approv modest launch
approv mdd bipolar
insomnia
initi phi data healthi volunt
initi phii studi patient essenti tremor sage-
initi phi trial healthi volunt
zuranolon initi phiii trial acut
clariti regard path forward
fda meet address amend
view explan region hierarchi
research highest favor quintil
approv larg set
pipelin continu progress rang
phiii readout delay
achiev modest efcaci
approv narrow set indic
brexanolon fall short target penetr
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
long-term prospect sarepta dmd franchis drive risk/reward
pt deriv dcf use discount rate termin growth
beyond valu sarepta dmd franchis
overweight thesi base
strong initi dmd genetherapi data
manag abil captur signic
market share dmd gene therapi
believ initi data derisk
program provid signic upsid
base busi exon skip drug
pipelin larg divers offer
lgmd potenti upsid driver
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
exondi continu expand market
exondi continu expand market
share golodirsen achiev rapid
share golodirsen achiev rapid
sale casimersen approv srp-
gene therapi drive bulk
valuat assum approv
continu strength exondi well
continu strength exondi well
golodirsen launch assum camisersen
approv risk-adjust dmd
gene therapi expect
launch
assum lower peak penetr
assum lower peak penetr
exondi modest golodirsen sale
exondi modest golodirsen sale
approv camisersen downstream
eros usag includ revenu
complet phii/iii dose patient mp iiia
initi conrmatori trial dmd patient exondi
phi/ii data high dose cohort
phi/ii data high dose
initi phi/ii trial
view explan region hierarchi
research highest favor quintil
addit regulatori approv expand
reimburs exon-skip therapi
continu demonstr efcaci
long-term durabl treatment
updat dmd gene therapi program
includ risk relat manufactur
on-going regulatori discuss
data competitor compani could
neg impact sarepta posit dmd
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
pipelin option vs manag legaci product eros drive risk-reward
deriv pt discount cash ow dcf analysi use wacc
termin growth rate post bear case main revenu driver
model eros base busi due biosimilar matur late-
overweight believ
upsid pipelin recent launch
help reduc long-term risk
compani current base busi face
biosimilar exibl add
potenti in-organ growth
stabl base even biosimilar
believ protect key franchis
biosimilar competit near-
term long-term forecast
gradual share shift biosimilar versu
cliff key product neulasta enbrel
project period
divers pipelin under-
appreci see upsid consensu
estim lung cancer
bite platform anti-inamm asset
biosimilar portfolio
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
lower biosimilar impact coupl
lower biosimilar impact coupl
outsiz revenu pipelin
outsiz revenu pipelin
assum pipelin sale
tezepelumab bite peak
biosimilar revenu
aimovig sale
modest line penetr kyproli
peak sale
enbrel long-term patent hold
biosimilar enter market
us biosimilar impact similar trend
us biosimilar impact similar trend
europ modest result
europ modest result
pipelin assum pipelin
sale tezepelumab
bite platform peak biosimilar revenu
aimovig sale
modest line
penetr kyproli peak
sale enbrel biosimilar start
take share
view descript risk reward theme
assum pipelin failur
kyproli relapsed/refractori
market peak sale
biosimilar expos product
quickli enbrel expos biosimilar
earli weak aimovig
repatha growth
bcma hle-bit initi clinic data multipl
proof concept data inammatori diseas
anticip launch next phase develop
enbrel appeal outcom reveal led sandoz
updat statu
continu launch perform aimovig
erenumab approv launch amgen
biosimilar molecul advanc
potenti launch pipelin product
tezepelumab
view explan region hierarchi
research highest favor quintil
better-than-expect pipelin success key
cost efcienc
greater eros legaci product
limit bite success solid tumor
failur late-stag pipelin particularli
tezepelumab otezla label
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
filgotinib ra ibd pipelin asset drive risk/reward
glpg price target base dcf use discount rate termin
growth rate explicit revenu project revenu project
incorpor lgotinib royalti variou inammatori diseas includ ra cd uc
addit sale ipf sale oa risk includ
regulatori risk develop risk ipf competit market
equal-weight galapago
believ lgotinib addit pipelin
asset differenti carv
market share competit
product though anticip addit
data later stage pipelin product
filgotinib differenti prole
versu oral competitor xeljanz
olumi drug may approv
black box warn
filgotinib potenti approv
key inammatori indic beyond
ra includ crohn diseas ulcer
coliti ankylos spondyl psoriat
date data pipelin asset
ipf oa
encourag
filgotinib still major driver
filgotinib still major driver
assum greater share ra
assum greater share ra ipf oa
assum po adjust peak
sale lgotinib ra
uc cd
payment ipf
gener peak po adjust global sale
oa gener peak
po adjust global sale
filgotinib drive forecast strong
filgotinib drive forecast strong
contribut ipf oa pipelin
contribut ipf oa pipelin
asset assum po
adjust peak sale lgotinib ra
uc
cd total
lgotinib mileston payment
ipf gener peak po
adjust global sale
oa gener peak po
adjust global sale
filgotinib pipelin asset fail
manag continu invest
assum cash-per-share valu
 top-line phiib data osteoarthr roccella
top-line data
anticip launch lgotinib ra eu japan
filgotinib phiii divers studi data releas lgotinib
crohn
phiii select studi data releas lgotinib uc
main driver advanc lgotinib
ra ibd along continu progress
ipf oa program
view explan region hierarchi
product greater risk-adjust may
succeed late stage trial
phase studi could take signic time
phase ii safeti prole may assur
protect unknown side-effect
filgotinib pipelin product may
placebo rate may higher expect
phiii ipf selction trial
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
darzalex label expans matur mid-lat stage pipelin drive growth
pt deriv dcf use discount rate termin
growth rate revenu driver model darzalex late-stag partner product
ofatumumab teprotumumab well earli stage proprietari compound
overweight thesi base
signic upsid skew risk/reward
proprietari pipelin believ
current valuat genmab support
exclus darzalex royalti
upsid
believ darzalex royalti worth
coupl
late-stag pipelin ofatumumab ms
teprotumumab ofa tepro could
believ earli mid-stag
proprietari pipelin under-valued
consensu repres compel
risk/reward valu proprietari
pipelin base case
bull case valuat
success ms greater risk-adjust
success ms greater risk-adjust
valu proprietari pipelin
valu proprietari pipelin
assum peak sale darzalex
ofatumumab peak sale
pipelin peak sale
ofatumumab success ms risk-adjust
ofatumumab success ms risk-adjust
valu proprietari pipelin
valu proprietari pipelin
assum peak sale darzalex
ofatumumab peak sale
pipelin peak sale
assum blend probabl
darzalex royalti valu
darzalex royalti valu bear case
assum darzalex royalti burden
invest pipelin
matur assum greater
competit out-year
biosimilar cell therapi mm
base case
phiii readout daratumumb al amyloidosi
phii readout daratumumb nktcl nasal volan
updat potenti partner
pivot phii readout tisotumab vedotin cervic cancer
phii readout daratumumb delphinu
ofatumumab label expans rr ms
teprotumumab commerci
variou proprietari partner product initi
clinic readout
pivot phii data innovatv
tisotumab vedotin cervic cancer earli
view explan region hierarchi
darzalex may continu show growth
darzalex could face greater competit
meet consensu expect
competitor ocrevu
early-stag proprietari asset could fail
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
breo anoro eros drive risk reward
pt deriv dcf assum discount rate termin growth
underweight see
limit upsid valuat impli
potenti gsk consolid
royalti interest breo/anoro
launch breo anoro
sluggish far
laba/ class mean growth
expect maba/tripl combo
trelegi royalti cannib sale
breo
breo anoro captur signic share
breo anoro captur signic share
market impact trelegi less
market impact trelegi less
signic bull case assum breo
anoro characterist qd dose
breo lack ic anoro
drive major share copd asthma
rx given sluggish launch
drug physician familiar
approv laba/icss see scenario
unlik model peak ww sale
breo anoro
trelegi
breo anoro sluggish launch
breo anoro sluggish launch
trelegi cannib breo sale case
assum breo anoro gain
modest share copd/asthma
prescript model peak ww sale
breo anoro
trelegi
breo anoro falter commerci upsid
breo anoro falter commerci upsid
cannib breo/anoro trelegi
cannib breo/anoro trelegi
bear case assum breo anoro fail
gain commerci traction model ww
sale breo anoro
trelegi
key driver model includ royalti
breo launch anoro launch
trelegi approv
view explan region hierarchi
research highest favor quintil
gener advair trelegi may erod
breo/anoro sale less expect
breo and/or anoro may sell better
compani may potenti strateg
busi develop transact may
continu growth gadvair on-going
share caus unfavor mix shift
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
note suffici broker suppli
consensu data metric
note suffici broker suppli
consensu data metric
note suffici broker suppli
consensu data metric
arikayc peak sale success drive valuat
pt deriv dcf use discount rate termin growth rate
revenu driver model ali market penetr us japan refractori
frontlin mainten treatment ntm
overweight thesi base base-
valu arikayc upsid option valu
see peak arikayc sale
modest assumpt chronic dose
geograph expans japan provid
addit lever see substanti
foreign sale larger ntm popul
despit lower price ntm
preval japan
strong phii data demonstr
feasibl potenti treatment
patient non-cf bronchiectasi ncfbe
larg untap market high
potenti upsid also see
opportun addit indic
upsid arikayc ramp penetr
upsid arikayc ramp penetr
 japan
 japan arikayc continu grow
 launch japan
achiev penetr
respect refractori ntm
penetr frontlin popul
us japan peak sale
succe upsid penetr
broad label non-cf bronchectasi
 pos-adj peak sale
signic arikayc penetr
signic arikayc penetr
japan
japan follow consist growth
 market expect drug
launch japan reach
penetr respect
modest frontlin penetr us japan
peak sale
non-cf bronchectasi
commerci pos-adj
peak sale
limit continu ramp arikayc
limit continu ramp arikayc
arikayc achiev peak sale
us
initi trial arikayc frontlin ntm patient
final tool frontlin
submit nebul applic japan
expans arikayc eu japan
follow-up data long-term extens
full phii data non-cf
view explan region hierarchi
research highest favor quintil
may show posit phiii data non-cf
failur reach market frontlin
popul weak penetr
investor concern demand
delay life cycl manag studi
need obtain robust mainten front
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
strength adcetri matur mid/late-stag pipelin asset key driver
pt deriv dcf use discount rate termin
growth rate revenu driver model adcetri sale eu/row adcetri
royalti revenu estim also includ risk-adjust sale estim partner
product enfortumab vedotin tisotumab vedotin addit wholly-own tucatinib
equal-weight thesi base
estim continu growth adcetri
treatment chl certain subtyp
nhl see key growth driver
increas uptak exist indic
potenti label expans growth
earlier line therapi
patient muc
vedotin tucatinib potenti
take share metastat cervic
technolog
out-licens number
compani rm entitl
mileston royalti payment
growth strong tisotumab vedotin
growth strong tisotumab vedotin
uptak adcetri driven label
expans model peak canada
adcetri sale peak
ex-u royalti seattl genet
assum
commerci padcev
peak revenu sourc
model pos-adj sale tucatinib
prot share sale tiso
continu adcetri growth padcev
continu adcetri growth padcev
approv tisotumab vedotin
approv tisotumab vedotin assum
continu uptak adcetri driven label
expans model peak canada
adcetri sale peak
ex-u royalti seattl genet
assum
commerci padcev
peak revenu sourc
also model pos-adj sale tucatinib
prot share sale
tiso
slower anticip growth adcetri
slower anticip growth adcetri
sale along weak penetr
sale along weak penetr
padcev tucatinib
padcev tucatinib tisotumab vedotin
along pipelin effort fail
 adcetri sale
peak ex-u adcetri sale
model peak canada
padcev sale peak
tucatinib sale
readout adcetri label expans studi
nivolumab combo studi frontlin hl
upcom readout tucatinib neoadjuv
pivot phii readout tiso cervic cancer
view explan region hierarchi
research highest favor quintil
competitor may fail commerci
product adequ compet
competit product may enter market
erod adcetri market share
advers impact delay approv
decienc safeti may uncov
product candid continu evalu
compani may fail achiev fda approv
label expans pipelin product
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
pivot phii readout tisotumab vedotin cervic cancer
initi phi trial undisclos product candid partner
beigen
phiii readout adcetri nivolumab vs adcetri
data ucd program drive risk/reward
pt deriv dcf use discount rate termin
growth rate revenu driver model ucd
greater diagnosi rate larger set
greater diagnosi rate larger set
address patient ucd vs
address patient ucd vs
base case
base case ucd
respect
assum kaleido program
approv overt minim patient
appli risk adjust
ucd program respect
ucd program approv
ucd program approv
therapeut receiv signic patient
therapeut receiv signic patient
uptak ucd
gener peak risk-adjust global sale
respect uptak
 drive bulk revenu due
greater share higher price
compar eu assum
kaleido program approv
overt popul appli
risk adjust ucd
overweight kaleido thesi
base success commerci
mmt product treatment urea
cycl disord ucd hepat
kaleido take differenti approach
toward leverag gut microbiom
develop synthet analyt
capabl enabl kaleido gener
non-ind studi healthi
toler prole abil reduc
nitrogen excret may translat
addit mdr program though
kaleido pipelin fail ucd
kaleido pipelin fail ucd
program fail kaleido unabl
program fail kaleido unabl
commerci mmt therapi
commerci mmt therapi
assum share trade cash value-per-share
case
 initi non-ind studi
 data non-ind studi patient colon
 data phii clinic studi ucd
data phii studi ucd
ind
kaleido program could produc data
yield less punit risk adjust
poor phii data ucd patient
make investor question viabil
neg data microbiom
compani weigh share
regulatori chang compromis kaleido
abil conduct non-ind studi human
may lengthen time market
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
probabl success monoclon microbi therapi drive risk/reward
deriv pt discount cash ow analysi assum wacc
termin growth rate revenu driver model evelo lead monoclon
microbi product candid atop dermat psoriasi
signic share ad psoriasi
signic share ad psoriasi evelo
launch ad psoriasi
share peak patient control
topic treatment psoriasi evelo
obtain share peak
patient biolog oral respect
assum probabl success
po atop dermat po
psoriasi estim peak pos-adjust
revenu
modest share atop dermat
modest share atop dermat
share peak atop dermat
patient control topic
treatment gain share
peak psoriasi patient biolog
oral respect estim peak
pos-adjust revenu
treat system condit via gut-
bodi network nascent eld evelo
signic clinic literatur recent
year support premis gut-bodi
network preclin data gener
date evelo lead product candid
inamm oncolog encourag
initi phi data report recent lead
encourag efcaci signal psoriasi
substanti help derisk evelo
scalabl sever potenti target
therapeut inher safe
deriv gut
program fail valu compani
cash
phi/ii data oncolog indic
phib readout ad
phib data psoriasi
initi phib studi asthma
phii readout psoriasi
phi data atop dermat
phi/ii data oncolog indic
phii interim data
psoriasi late
data ad may demonstr superior
current approv treatment atop
earli setback microbiom focus
compani may weigh investor percept
futur readout replic
efcaci signal observ initi phi
unforeseen safeti signal upcom
readout
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
note suffici broker suppli
consensu data metric
pt base dcf use discount rate project free cash ow
base termin valu onward use termin growth rate
project revenu lead product candid tnbc muc
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
greater adopt ww peak risk
adjust sale assum
commerci treatment line
mtnbc acceler adopt muc
er cancer
base case assum launch
mtnbc addit revenu
stream earlier line muc er
larg enter assign
risk adjust use mtnbc ww
risk adjust sale
equal-weight driven concern
around uncertainti approv timelin
requir follow
sidelin
continu believ efcaci
safeti data see
signic unmet need mtnbc
believ approv could see rapid
adopt peak sale
believ obtain multipl
label expans increas asset total
address market studi front line
mtnbc muc breast cancer
view descript risk reward theme
bear case assum fail
receiv approv indic
stock trade cash valu
commerci launch mtnbc
phiii conrmatori studi ascent top-lin data
mtnbc
fda accelar approv bla resubmiss
phii top-lin data pivot cohort patient treat
platinum cpi trophi
remedi approv
phiii data random ascent studi
mtnbc treatment earlier line set
data hormon breast cancer muc
management correct cmc-relat issuesfast
competit landscap target
therapeut mtnbc muc increas
failur achiev signic label expans
earlier line therapi mtnbc
view explan region hierarchi
research highest favor quintil
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
pt deriv dcf use discount rate termin growth rate
beyond valu beigen four clinic stage product candid recent
acquir oper china
beigen posit focu i/o
differenti clinicalprol lead
asset varieti tumor type
global compani uniqu access
chines market chines patient
pool clinic develop provid
necessaryinfrastructur facilit
product china
uptak oncolog drug china
indic strong demand healthcar
insur reform grow market
time believecould serv
strong uptak china ex-
strong uptak china ex-
china market driven differenti
china market driven differenti
prole uniqu combin
prole uniqu combin
bgb-
beigen earn royalti
ex-china sale celgen
china portfolio gener annual
sale amgen china oncolog
portfolio gener annual sale
beigen abl launch four
beigen abl launch four
modest uptak within outsid
modest uptak within outsid
bgb-
beigen earn royalti
ex-china sale celgen
china portfolio gener annual
sale amgen china oncolog
portfolio gener annual sale
view descript risk reward theme
failur develop launch
molecul combin therapi
china ex-china market
potenti submit nda pamiparib oc
mut china
submit snda tislelizumab squamou nsclc
snda ling zanubrutinib wm china
receiv approv zanubrutinib china treatment
patient r/r mcl r/r cll/sll
top-lin tislelizumab data global portion phiii
nsclc global phiii
updat global penetr btk
develop commerci multipl
portfolio partnership china
view explan region hierarchi
research highest favor quintil
demonstr surpris superior key
compet compound later-stag
penetr china market quickli
expect enter nrdl
inadequ efcaci and/or safeti data
on-going clinic trial particularli
tislelizumab nsclc zanubrutimab
regulatori chang china compromis
beigen prefer develop posit
access china market
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
